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Abstract 
Common eye diseases such as dry eye syndrome affect 15% of the population. Although eye drops are 
the most common treatment for these diseases, over 95% of the drugs applied through eye drops are 
quickly cleared away due to blinking and tear turnover. Consequently, patients struggle with the 
multiple daily applications required and the resulting side effects. 
Nanoparticle (NP) drug carriers have gained significant traction recently because of several 
advantages they provide over conventional eye drop delivery methods. NP surfaces can be tuned to 
achieve specific properties such as binding affinity towards the ocular surface. NPs can also carry a 
large amount of drugs and release them in a sustained manner over a long period. Due to their small 
size, NPs do not cause abrasive sensations on the eye upon patient application. With these unique 
advantages, NP drug carriers may drastically improve patient compliance while reducing side effects. 
The thesis focuses on developing an ocular drug delivery platform using NPs to improve retention 
of ocular therapeutics on the precorneal surface. We developed a method to synthesize an amphiphilic 
block copolymer composed of poly(D,L-lactide) (PLA) and dextran (Dex) that can self-assemble into 
NP drug carriers. The size of the NPs can be tuned between 15 and 70 nm by adjusting the molecular 
weights of PLA and/or Dex. The PLA-b-Dex NPs form the foundation of the ocular drug delivery 
platform developed in this thesis. 
A targeted delivery system is crucial for ocular drug delivery due to the rapid clearance by tear 
drainage on the corneal surface. The PLA-b-Dex NPs were surface modified with phenylboronic acid 
(PBA) molecules, which can undergo covalent binding with the mucous membrane to circumvent the 
rapid clearance. Due to the abundance of functional groups on the dextran, we were able to tune the 
density of PBA on the NP surface to optimize the binding affinity between the NPs and the mucin. 
While maximizing the PBA density on the NP surface improved the covalent interaction between the 
NPs and the mucin, it also compromised the NP colloidal stability. The PBA modified NPs 
demonstrated encapsulation of Cyclosporine A (CsA), a dry eye treatment drug, and sustained release 
for up to 5 days in vitro, showing their potential as a long-term eye drop delivery platform. 
We then performed biocompatibility and efficacy studies on these NPs using animal models. 
Biocompatibility is of the utmost importance in developing new drug delivery formulations. During the 
12 weeks of study, no physical signs of irritation or discomfort were detected nor was any inflammatory 
response or ocular tissue damage observed in the eyes administered with NPs. Topical administration 
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of CsA-loaded NPs on dry eye induced mice using once a week dosing demonstrated complete 
elimination of the inflammatory response as well as full recovery of the integrity of the ocular tissues. 
In the same study, the commercial eye drop form of CsA, Restasis®, administered thrice daily only 
eliminated the inflammatory infiltrates without recovering ocular goblet cells. By delivering CsA 
through PLA-b-Dex-g-PBA NPs, we can significantly reduce the dose and the frequency of eye drop 
administration without compromising the treatment efficacy. 
In vitro mucoadhesion as a result of PBA’s on NP surfaces was demonstrated. We proceeded to 
further demonstrate this mucoadhesion using in vivo models. Indocyanine green (ICG), a near-infrared 
fluorescent dye, was encapsulated in the NPs and administered to rabbit eyes to track its ocular 
retention. ICG delivered via PBA modified NPs showed ocular retention beyond 24 hours on rabbit 
eyes, whereas free ICG or ICG delivered via unmodified NPs were mostly cleared within the first 3 
hours. When the weekly dosing of CsA loaded PLA-b-Dex-g-PBA NPs was repeated for 4 weeks on 
dry eye induced mice, we observed the same elimination of inflammatory infiltrates but also the 
damaged ocular tissue structures. When the concentration of the CsA in the weekly dosing of NPs was 
further reduced 5 times, the treatment effect was much more pronounced, showing both the elimination 
of the inflammation and the full recovery of the ocular surface tissues. Overall, by using mucoadhesive 
nanoparticle drug carriers, we reduced the dosage of CsA at least 50-fold compared with the 
commercial product, Restasis®, without compromising the dry eye treatment efficacy. 
Finally, we developed a scalable method to synthesize PLA-b-Dex-g-PBA block copolymers using 
a semi-solid state reaction chemistry. The previous method of conjugating PBA to the Dex required 
long reaction hours with multiple reaction and purification steps. In contrast, the new method combines 
the quickness of a semi-solid state reaction with the simplicity of a Williamson ether chemistry to graft 
PBA to Dex. The results showed that the new method achieved a similar range of tunability of PBA 
density onto Dex using reaction times as short as 10 minutes.  
This thesis demonstrates the development process of a polymeric NP as a topical ocular drug delivery 
system. The PLA-b-Dex-g-PBA NPs demonstrated delivery of a clinically relevant dosage of dry eye 
therapeutics, controlled release of therapeutics over prolonged period of time, and mucoadhesive 
properties resulting in prolonged ocular surface retention of drugs. These mucoadhesive NPs show 
remarkable promise as a long-term topical ocular drug delivery system that significantly reduces the 
dose and the administration frequency of the eye drops while minimizing side effects.  
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Chapter 1 
INTRODUCTION 
1.1 Overview 
A significant population of the world suffers from some form of eye disease. The severity of eye 
diseases ranges from daily complications to blindness. Dry eye syndrome is one of the milder forms of 
eye diseases that cause dryness in the eye as a result of a reduced rate of lacrimation or increased rate 
of tear film evaporation. This condition affects about 4.9 million individuals in the United States alone, 
causing ocular surface irritation and inflammation [5]. Although its symptoms may be mild, if left 
untreated, dry eye syndrome can lead to various infectious diseases on the ocular surface.  
Topical administration, typically in the form of eye drop formulations, is the most common delivery 
method employed for treating diseases associated with anterior segments of the eye. Although simple 
to use, topical administrations suffer from low ocular surface retention as a result of rapid drainage 
through the naso-lacrimal duct, near-constant dilution by tear turnover, and low drug permeability 
across the corneal epithelium [6]. Therefore, eye drops are normally administered multiple times daily 
in order to achieve therapeutic efficacy – this, however, also leads to an increased risk of side effects 
and lowered patient compliance. 
Nanomedicine—the fusion of nanotechnology and medicine—has been a focal point of research in 
the field of ocular drug delivery in the past decades [1, 7-10]. Nanoparticle (NP) drug carriers have the 
potential to overcome challenges posed by current eye drop formulations. NPs are particles with sub-
100 nm sizes that can encapsulate and deliver therapeutic agents. They have high surface area-to-
volume ratios and the surfaces of the NPs can be tuned to achieve specific surface properties such as 
adhesion to ocular mucous membranes for prolonged retention. NPs can also release the encapsulated 
therapeutics in a sustained manner for prolonged treatment of the ocular diseases. Because of their 
small size, NPs do not cause abrasive sensations on the surface of the eye, improving patient comfort. 
The thesis explores the application of NPs as a drug delivery platform to enhance the delivery of 
therapeutics to the ocular surface. A polymeric NP self-assembled from a block copolymer was 
developed as the ocular drug delivery platform. The surfaces of these NPs were chemically modified 
with phenylboronic acid (PBA), which can covalently target the sialic acid moieties that are abundant 
on the ocular mucous membrane. Cyclosporine A, a commercially used drug for the treatment of dry 
eye, was used as a model drug to determine the capability of the PBA-modified NPs to encapsulate and 
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release the drugs. In preclinical studies, the safety of the Cyclosporine A-loaded NPs was evaluated in 
animal models and their dry eye treatment efficacy was also tested. Further animal studies were used 
to analyze the mucoadhesive properties of the NPs to calculate their ocular retention time, and the 
dosage of the Cyclosporine A in the NP formulation was tuned for the long term treatment of dry eye. 
Finally, an improved methodology was developed to process the PBA-modified block copolymers in a 
scalable way. Some of the avenues to explore in the future to advance this NP drug delivery platform 
into clinical trials include developing a good manufacturing practice (GMP) process for the NP drug 
delivery platform and good laboratory practice (GLP) studies to further investigate the safety and 
efficacy of the NP formulation. 
1.2 Research objectives 
The overall objective of the proposed project is to develop a nanoparticle drug delivery system capable 
of enhancing the therapeutic efficacy of topical formulations targeting anterior segments of the eye. To 
develop a nanoparticle drug delivery system, we start by designing a block copolymer that can self-
assemble into nano-sized micelles capable of encapsulating and controlling the release of therapeutics. 
The nanoparticles are characterized for mucoadhesion, drug encapsulation, and release in vitro before 
performing in vivo tests. Subsequent in vivo tests involve testing the biocompatibility and efficacy of 
the nanoparticle formulations. Finally, a scalable process for synthesizing the block copolymer must be 
developed to demonstrate the feasibility of the formulation for clinical trials. The specific objectives of 
the study are as follows: 
1. Develop a polymeric nanoparticle drug delivery system 
 Synthesize a block copolymer, through conjugation of hydrophobic poly(D,L-lactide) 
(PLA) and hydrophilic dextran, that self-assembles into nanoparticles 
 Characterize the size, morphology, and drug delivery capacity of the nanoparticles formed 
from PLA and Dex 
2. Develop a mucoadhesive nanoparticle drug carrier for topical ocular delivery applications 
 Demonstrate the mucoadhesion properties of the phenylboronic acid (PBA) functionalized 
nanoparticle carriers 
 Demonstrate the capability of the nanoparticles to encapsulate and delivery ocular 
therapeutic agents 
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3. Demonstrate the in vivo biocompatibility and efficacy of the nanoparticles as a platform delivery 
system to target the anterior eye 
 Demonstrate the biocompatibility and non-irritancy of the nanoparticle formulation in 
rabbit models 
 Demonstrate the treatment efficacy by delivering Cyclosporine A using mucoadhesive 
nanoparticles to mice with experimentally induced dry eye 
4. Demonstrate the prolonged ocular retention of nanoparticles and adjust the dosage of Cyclosporine 
A in the nanoparticles for long-term treatment of dry eye in mice 
 Investigate the ocular retention time of the nanoparticles on the ocular surface 
 Determine the optimal dosage of Cyclosporine A in the nanoparticles for the long-term 
treatment of dry eye in mice 
5. Develop a scalable synthesis process for PBA modified PLA-Dex block copolymers using semi-
solid state reaction mechanisms 
 Develop a fast, simple, and scalable process for synthesizing PBA-modified PLA-Dex 
copolymers 
1.3 Thesis outline 
This thesis is comprised of eight chapters: the introduction, a literature review, five experimental 
research based chapters, and a final chapter featuring the conclusion and recommended future work. 
Chapter 1 introduces the key challenges to be addressed in the thesis, the hypothesis, and the specific 
objectives to test this hypothesis. 
Chapter 2 reviews the current status of the field of ocular drug delivery. Various types of 
nanomaterials currently being investigated in the field of ocular drug delivery are discussed and their 
advantages and disadvantages are outlined. The future outlook of nanomaterial-based ocular drug 
delivery vehicles is also highlighted. 
Chapter 3 describes the method of the synthesis of an amphiphilic block copolymer and the in vitro 
characterization of the nanoparticles formed from the self-assembly process. The block copolymer is 
an initial building block of the nanoparticle drug carriers, which then becomes the delivery platform 
for us to explore various ocular treatment options. 
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Chapter 4 presents the method of modifying the surface of PLA-Dex nanoparticles with PBA to 
achieve mucoadhesive targeting. This is a crucial step in prolonging the retention of drugs delivered to 
the ocular surface. This study demonstrates the potential of the nanoparticle drug carrier system to serve 
as an enhanced drug delivery platform for treating ocular diseases. 
Chapter 5 follows the in vitro characterizations of Chapter 4 with the in vivo characterization of the 
biocompatibility and the treatment efficacy of this mucoadhesive nanoparticle formulation. This study 
provides the foundation for the further advancement of this platform delivery system into clinical trials, 
after demonstrating both the preliminary biocompatibility and treatment efficacy in preclinical settings. 
Chapter 6 further explores the in vivo examination of the mucoadhesive properties of the 
nanoparticles as well as the dosage-dependent dry eye treatment efficacy of the nanoparticles carrying 
Cyclosporine A. The chapter investigates the ocular retention time of drugs delivered by the 
nanoparticles using live imaging of the drug molecule on animals, as opposed to more commonly used 
methods of post-euthanasia analyses. Due to the mucoadhesive nature of the delivery system, the dose 
and the dosing frequency of the formulation must also be carefully controlled to prevent any side 
effects. 
Chapter 7 revisits the discussion from Chapters 3 and 4 to improve the synthesis process for the PBA-
modified block copolymer. One of the key milestones to meet before proceeding to clinical trials is to 
develop a scalable manufacturing process for the formulation. Chapter 7 explores a novel semi-solid 
state reaction mechanism to achieve a simple, fast, and scalable way of producing the block copolymers. 
Chapter 8 highlights the conclusions drawn from the research described in Chapters 3 to 7 and 
recommendations for future work based on these conclusions. While Chapter 7 discusses the 
importance of a scalable process for the copolymer building block, another important step before 
proceeding to clinical trial is to also provide a manufacturing process for the nanoparticle-drug 
formulation. Finally, an important future goal is to explore the flexibility of the nanoparticle drug 
delivery platform to treat other common ocular diseases in addition to dry eye syndrome, such as 
glaucoma and allergic conjunctivitis. 
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Chapter 2 
LITERATURE REVIEW 
2.1 The field of ocular drug delivery 
Ocular drug delivery remains a challenging task due to the nature of the ocular structures and the unique 
ocular physiology. The eye is a small and complex organ that is separated from the rest of the body by 
multiple layers of biological barriers. Moreover, the eye tissue is protected from the external 
environment by the tight junctions of the corneal epithelium and the mucosal surface. Therefore, the 
primary challenge of ocular drug delivery is to circumvent these protective barriers in order to achieve 
therapeutically effective concentrations of drugs in the intraocular tissues. The objective of ocular drug 
administration is to treat diseases in a localized manner as opposed to serving as an intermediate route 
to achieve systemic drug activity.  
There are a plethora of vision-threatening ocular diseases that require therapeutic treatment, and most 
of these diseases are associated with intraocular structures such as the retina, retinal pigment epithelium 
(RPE), or choroid.[11] Typically, anti-inflammatory drugs, anti-microbial agents, and angiogenesis 
inhibitors are used to treat various types of local infections or disorders such as chronic uveitis, 
glaucoma, endophthalmitis and choroid neovascularization among many; nevertheless, the efficiency 
with which these substances are successfully delivered has largely been limited by the presence of 
ocular barriers. To date, most common ophthalmic drugs are administered topically in the form of eye 
drops on the corneal surface. However, topically administered drugs suffer from low bioavailability 
due to clearance mechanisms such as tear turnover. Alternative delivery methods such as intravitreal 
or periocular injections have been developed to improve the bioavailability of the therapeutic agents, 
but due to the invasive nature of these methods, side effects such as retinal detachment or intravitreal 
hemorrhage have been observed. The challenges affiliated with these conventional methods of ocular 
drug delivery have lead scientists to contribute significant effort into developing advanced drug 
delivery systems.  
At present, nanocarrier-based ocular drug delivery systems appear to be the most promising tool to 
meet the primary requirements of an ideal ocular delivery system. Nanocarriers, due to their small sizes, 
are likely to have high diffusivity across membranes such as the corneal epithelium: a significant 
number of studies have already demonstrated that the use of such nanomaterials via topical 
administration improved the corneal permeability of drugs.[12-15] Similarly, due to their high surface-
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area-to-volume ratio, nanocarriers may also show improved interaction with the mucous membrane of 
the corneal surface to prolong the retention of the topically administered drug formulations. Ongoing 
advances in developing improved nanocarrier-based ocular drug delivery system may also provide new 
possibilities of effectively delivering therapeutic agents to intraocular tissues such as the retina or 
choroid using non-invasive delivery methods. The following literature review highlights some of the 
most recent findings in the utilization of nanomaterials, such as polymeric micelles, hydrogels, 
liposomes, niosomes, dendrimers, and cyclodextrins, for enhanced ocular drug delivery performance 
(Figure 1). 
 
Figure 1. A schematic illustration of different nanomaterial-based ocular drug delivery systems. 
Polymeric micelles are nanoparticles self-assembled from amphiphilic copolymers with the 
ability to encapsulate hydrophobic drugs in the core of the particles. Hydrogel colloids are 3D 
network of water-soluble polymers which have the ability to incorporate hydrophilic drugs in 
the 3D network. Liposomes/niosomes are vesicle structures with both lipophilic and hydrophilic 
phases, and therefore can encapsulate both hydrophobic and hydrophilic drug components. 
Dendrimers are 3D highly branched tree-structured macromolecules that can encapsulate 
hydrophobic drug molecules since they possess internal empty cavities and open conformations 
for low generation dendrimers. Cyclodextrins are a family of cyclic oligosaccharides, composed 
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of 6 to 8 glucose units which have been shown to improve pharmacokinetic properties of many 
drugs through formation of inclusion complex.[1]  
2.2 Challenges of conventional ocular drug delivery system 
Difficulties in delivering drugs through the ophthalmic route arise from the anatomy and the physiology 
of the eye, an organ which is divided into anterior and posterior segments (Figure 2). Topical drug 
administrations, such as eye drops, suspensions, or ointments, are the most preferred route of delivery 
to the anterior segment of the eye due to the ease of administration and low cost. However, local drug 
administration to the anterior portion of the eye by topical application is significantly limited by the 
clearance mechanisms of the corneal surface, which include lacrimation, tear dilution, and tear 
turnover.[6] In addition, topically administered drugs are generally absorbed either through the corneal 
route (cornea  aqueous humor  intraocular tissues) or non-corneal route (conjunctiva  sclera  
choroid/RPE),[6] which further limits the amount of drug that is ultimately absorbed in the intraocular 
tissues. Due to these clearance mechanisms and ocular barriers, less than 5% of the total administered 
drug reaches the aqueous humor.[16] For example, after administration of a common eye-drop solution 
containing 0.05% cyclosporine to treat dry eye syndrome, more than 95% of the drug reaches systemic 
circulation through transnasal or conjunctival absorption.[17] 
The administration of drugs to the posterior portion of the eye is even more challenging due to the 
lack of cellular components in the vitreous body which reduces the convection of molecules to the 
posterior segments. Efficient drug delivery to the posterior segment of the eye is a challenge faced by 
many pharmaceutical researchers, as most blindness-inducing diseases are associated with the posterior 
segment.[18] Systemic administration has also been used to deliver therapeutic agents to the posterior 
segment of the eye; however, this route of administration requires large administration doses because 
of the inner and outer blood-retinal barriers that separate the retina and the vitreous humor from the 
systemic circulation:[19] studies to date have shown that less than 2% of systemically administered 
drugs reaches the vitreous cavity. High administration doses or frequent administration directly 
translates to poor patient compliance and increased risk of systemic side effects. 
Recently, intravitreal injections and vitreal implants have been investigated in order to achieve 
therapeutic concentrations at the posterior segment, although both intravitreal injections and vitreal 
implants are very invasive methods with high degrees of risk.[12] Frequent administration through the 
intravitreal route is associated with short-term adverse effects such as retinal detachment, 
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endophthalmitis, intravitreal hemorrhage, and increased risk of cataract development.[6, 14] More 
recently, periocular drug delivery has been investigated as a less invasive method, compared to 
intravitreal administration, in order to achieve high drug concentrations in the vitreous cavity.[22] 
Periocular administration refers to the injection of the drug in the vicinity of the ocular organ, such as 
the sub-conjunctival, sub-tenon, or parabulbar regions, so that the drugs can reach the vitreous cavity 
by crossing the sclera, choroid, and RPE barriers.[22] However, periocular drug administration is not 
without side effects: rise in intraocular pressure, cataract development, hyphema, strabismus, and 
corneal decompensation have been observed for some patients following periocular injections.[6] As a 
result, topical drug delivery carriers that possess enhanced permeability across corneal membranes and 
prolonged retention of the carriers in the ocular moiety are still largely preferred over intravitreal or 
periocular injections due to the invasive nature of the latter methods. 
 
Figure 2. The anatomy of the eye illustrating various ocular barriers and various mechanisms 
of drug delivery: 1. Topical administration, 2. Intravitreal injection, 3. Periocular injections (3a. 
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sub-conjunctival, 3b. peribulbar, 3c. sub-tenon, 3d. retrobulbar), and 4. Systemic 
administration.[1]  
2.3 Contact lenses in ocular drug delivery 
Earlier advancement in ocular drug delivery came from the idea of using contact lenses as sustained 
drug delivery system.[6, 23-25] In 2007, there were about 35 million contact lens wearers in North 
America alone, and the number is expected to have risen continuously to date.[26] The idea of using 
contact lenses as drug delivery tools, therefore, has been considered very practical. The contact lens 
drug delivery systems are typically prepared by soaking commercial lens products, such as silicone-
hydrogel, in a drug solution, allowing retention of drugs in the hydrogel matrix. Subsequently, the drug 
is allowed to be released at the corneal surface upon application of the lens on the eye. The purpose of 
using a contact lens drug delivery system is to increase the residence time of drugs on the corneal 
surface, compared to topical applications, so as to increase the amount of corneal absorption of these 
drugs. A mathematical model was used to postulate that as much as 50% of the drug released from 
contact lens could be absorbed by the cornea, but in vivo studies have yet to confirm the hypothesis.[27] 
The drug release from the lens is governed by a diffusional mechanism, which may often result in burst 
release of drugs for initial few hours.[28] Therefore, several studies have focused on using additional 
components in the contact lenses to control the release rate of the drugs. 
Ciolino et al. used the formulation of poly(lactic-co-glycolic) acid (PLGA) film, which is an FDA 
approved biocompatible polymer that has shown to be able to control drug-release kinetics, coated with 
poly(hydroxyethyl methacrylate) (pHEMA) hydrogel layers to control the release of ciprofloxacin.[28] 
The formulation resulted in steady zero-order release of ciprofloxacin up to 4 weeks. When the PLGA 
film was not present, ciprofloxacin released at a rate more than 3 times faster from pHEMA hydrogel 
than from the PLGA-pHEMA combination. Several of more recent studies examined the usage of 
nanomaterial-laden hydrogel contact lenses to achieve controlled drug release phenomena.[2, 29-31] 
Nevertheless, nanomaterial-laden contact lens drug delivery systems still face challenges in practical 
applications. The obvious challenge is that with the controlled release mechanism, the duration of the 
therapeutic window is also prolonged. This means that the patient must wear the lenses for a longer 
period of time which may cause discomfort in the eyes. Another challenge is that the diffusional-based 
drug release mechanism still causes some of the drugs to be released in the pre-lens tear film, as opposed 
to the post-lens tear film (i.e. between the cornea and the lens), which are also exposed to clearance 
mechanisms similar to topical administration. Lastly, the nanomaterials that allow slow release 
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mechanism may also trap the drugs permanently in the hybrid hydrogel matrix, which is shown in 
PLGA-pHEMA layers: only about 10% of the total drug from the contact lens was released during the 
sustained release phase. [28] This implies that the drug shelf-life must be long enough so that efficient 
amount of drug will be absorbed by cornea before losing its therapeutic efficacy. In general, the 
incorporation of nanomaterials in the contact lens must also not compromise some of the key properties 
of the lens itself such as biocompatibility, transparency, comfort and wettability. Much progress has 
been made in applying contact lenses as drug delivery system in order to overcome the challenges 
outlined previously. With the advent of nanomaterials, the contact lenses are potentially one of the more 
convenient ways of delivering ocular drugs. 
 
Figure 3. Schematic of nanoparticle-laden lens inserted in the eye (Reproduced with permission 
from[2]). 
2.4 Nanomaterials in ocular drug delivery 
Much research has been carried out on using different types of nanomaterials for the ophthalmic 
delivery of drugs. Sahoo et al. have outlined three major goals for ocular drug delivery nanocarriers: 1) 
enhancing drug permeation, 2) controlling the release mechanisms of drugs, and 3) modifying the 
surfaces of the nanocarriers with specific targeting moieties.[32] Due to the small size of these 
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nanocarriers, the permeability of these drug carriers through the vitreous barrier is greatly enhanced, 
which in turn improves the delivery rate of the drugs to the posterior tissues. Moreover, with the 
mucoadhesive properties exhibited by certain types of nanoparticles, drug carrier retention may be 
significantly prolonged in the targeted tissues. The nanocarrier-drug complex can be administrated as 
eye drop solutions requiring less frequent administration due to the higher retention of the drugs, 
reducing the cost of administration and increasing patient compliance. Zimmer et al. have suggested 
that the sizes of administered particles for ophthalmic applications must be less than 10 µm in order to 
avoid the sensation of scratching upon administration.[33] The potential advantages of using 
nanoparticles (NPs) for ocular drug delivery have been reviewed elsewhere.[34] 
The field of ocular drug delivery has been significantly impacted in the past decade by advances in 
technology, especially the development of nanostructured drug carriers. It was proposed that 
microspheres and nanoparticles used for the encapsulation of drugs would enhance the overall 
performance of ocular drug delivery systems.[33] The application of nanotechnology in the field of 
ocular drug delivery has been extensively reviewed by several groups. Gaudana et al. have highlighted 
recent advances in nanotechnology applications for ocular drug delivery, listing numerous 
nanostructure carriers as potential ocular drug carriers.[6] Ludwig has discussed the use of 
mucoadhesive polymer based nanostructures for the ophthalmic delivery of drugs, reporting the 
enhancement of targeting and retention of the drugs at the tissue site of interest such as corneal 
surface.[35] Nagarwal et al. have focused more on polymer-based nanoparticles, exploiting the 
application of the block copolymer micelles in the field of ocular drug delivery.[12] 
2.5 Nanomaterial-based ophthalmic formulation currently in the clinical stages 
The studies discussed thus far have focused on the initial proof-of-concept stage of nanomaterials in 
the field of ocular drug delivery. Table 1 below summarizes the progress of nanomaterial-based ocular 
drug delivery system in the clinical stages. The past few decades has seen significant increase in the 
number of journal articles published dealing with developing advanced ocular drug delivery system. 
Among these delivery systems, eye-drop formulations incorporated with various drug release-
controlling excipients (i.e. Polycarbophil) are currently available in the market.[36] A number of 
products in the form of intravitreal implant, inserts or punctal plug in the micro- or milli-scale are also 
currently being developed by various pharmaceutical companies.[36] Although numerous 
nanomaterial-based ocular drug delivery systems have already progressed onto the preclinical studies 
(i.e. in vivo animal studies) to characterize their pharmacokinetic properties in physiological 
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environment, very few of them have been analyzed in the clinical studies. Hydrogel carriers of timolol 
formulation showed improved control over the individual variation of timolol concentration in the 
aqueous humor among human patients compared to the pure drug suspension.[37] The lowered 
variation in drug concentration reduces the probability of having insufficient local drug concentration, 
and it also reduces the risk of toxic effects caused by an excessive amount of drug. Another interesting 
delivery method for trans-scleral iontophoresis was also studied in human patients using a hydrogel 
formulation.[38] Iontophoresis uses a small electric current to deliver charged therapeutic agents across 
biological membranes, and it has been extensively studied in ocular drug delivery due to the various 
ocular barriers.[25, 39-43] The hydrogel-iontophoresis delivery method in randomized human study 
demonstrated that total charge less than 60 mA•min were well tolerated by patients, rendering itself as 
a promising ocular drug delivery method for targeting both anterior and posterior segments of the eye. 
In addition to hydrogel ophthalmic delivery systems, incorporation of ophthalmic drugs with 
cyclodextrin has shown efficacy in lowering intraocular pressure in human patients.[44, 45] On the 
other hand, evaluations of nanomaterials such as micelles, liposomes/niosomes, and dendrimers are 
currently limited to the preclinical animal studies. However, these nanomaterials are also expected to 
be involved in clinical phase studies on human subjects in the near future as more preclinical studies 
demonstrate their enhanced pharmacokinetic properties. 
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Table 1. List of preclinical and clinical studies using nanomaterials in ocular drug delivery system 
Nanomaterial Drug Formulation Administration Treatment Clinical stage Ref 
Microsphere Triamcinolone acetonide PLGA (RETAAC) Intravitreal injection diabetic macular edema Launched [46] 
Micelles Dexamethasone NPIAAM-VP-MAA Eye-drop inflammation Preclinical [47] 
 Dexamethasone Pluronic F127-Chitosan Eye-drop ocular hypertension Preclinical [48] 
 Cyclosporin A MPEG-hexPLA Eye-drop dry eye, autoimmune 
uveitis 
Preclinical [49] 
 Dexamethasone PHEA-PEG Eye-drop ocular hypertension Preclinical [50] 
Hydrogel Timolol  Topical ocular hypertension Randomized  
human 
[37] 
   Transceral 
iontophoresis 
 Randomized  
human 
[38] 
Liposomes Flurbiprofen stearic acid + castor oil Eye-drop inflammation Preclinical [51] 
 Ciprofloxacin HCl chitosan coated liposome Eye-drop conjunctivitis Preclinical [52] 
 Fluconazole liposome Eye-drop fungal infection Preclinical [53] 
 Ciprofloxacin HCl chitosan coated liposome Eye-drop bacterial growth of P. 
aeruginosa 
Preclinical [54] 
 Bevacizumab liposome Intravitreal injection ocular neovascular 
activity 
Preclinical [55] 
 Verteporfin Liposome (Visudyne®) Intravitreal injection classic subfoveal 
choroidal 
neovascularization 
Launched [36] 
Dendrimer pilocarpine nitrate and 
tropicamide 
PANAM Eye-drop myosis and mydriasis Preclinical [56] 
 carteolol phosphorus-containing 
dendrimers 
Eye-drop glaucoma Preclinical [57] 
Cyclodextrin Methazolamide HPβCD and HPMC Eye-drop ocular hypertension Randomized  
human 
[45] 
 Latanoprost  Eye-drop open-angle glaucoma Randomized  
human 
[44] 
 14 
2.6 Recent developments of nanomaterials in ophthalmic formulations 
2.6.1 Polymeric micelles 
Polymeric micelles are core-shell structured nanoparticles formed by the self-assembly of amphiphilic 
copolymers. Polymeric micelles have been investigated extensively in the field of drug delivery as they 
present numerous advantages. Polymeric micelles can be fabricated through the simple self-assembly 
process, usually involving techniques such as nanoprecipitation, emulsion, or dialysis, in aqueous 
medium. In addition, the core-shell structure enables encapsulation of hydrophobic drugs in its 
hydrophobic core. Because the hydrophobic core is shielded by the hydrophilic corona, the stability 
and the half-life of the drug is significantly prolonged in the circulation. Moreover, biodegradable and 
biocompatible polymers are selected for formulation of micellar carriers, which would prevent any 
adverse effects caused in the physiological system by the carriers. With these benefits, polymeric 
micelles have attracted great interest in the field of drug delivery[42, 58-63], including drug delivery 
in ocular routes in the past several decades. 
Several groups in the past have used polylactide (PLA) or poly(lactide-co-glycolide) (PLGA) drug 
carriers to enhance the delivery of different types of drugs.[64-69] PLGA copolymers form micro- or 
nanoparticles in aqueous medium by self-assembly phenomena and can be used to encapsulate the 
drugs. However, the challenge with using PLGA carriers is that the polymer is unstable in aqueous 
medium: the ester backbone of the PLGA polymer is prone to hydrolytic degradation, which ultimately 
lowers the shelf-life of PLGA encapsulated drug complexes. Thus, many scientists have turned to 
investigating copolymers with hydrophilic chains, such as polyethylene glycol (PEG) or polyethylene 
oxide (PEO) in order to increase the stability of the nanoparticles by shielding the hydrophobic cores 
from hydrolytic degradation. In one study, the effect of PEG versus chitosan surface modification on 
polymeric micelles was compared in terms of the ability to penetrate and deliver drugs across the 
corneal membrane.[70] Chitosan was electrostatically anchored to the surface of PCL nanocapsules, 
whereas PCL-b-PEG was synthesized.  The results showed both nanocapsules increased the 
permeability of encapsulated drugs through the corneal epithelium compared to free drug suspension, 
with Chitosan coated nanocapsules increasing the amount of drug permeation up to three folds at 4 hour 
interval. However, the mechanism of transport enhancement remains to be completely dissected. A 
triblock copolymer poly(oxyethylene)-poly(oxypropylene)/poly(oxyethylene) (PEO-PPO-PEO, trade 
name: Pluronic F127) was suggested by Pepic et al. for encapsulation and delivery of pilocarpine.[71] 
The triblock copolymer is comprised of a central hydrophobic chain (PPO) with two hydrophilic chains 
  15 
on either side (PEO) which was shown to self-assemble into a micellar structure in aqueous 
environment with sizes ranging from 16 to 30 nm having pilocarpine encapsulated. Although the drug 
encapsulation efficiency was very low (maximal 1.9 wt%), the authors demonstrated that the miotic 
response (area under curve of miotic response vs. time)  using micellar solution of pilocarpine base 
showed 64% increase compared to standard pilocarpine eye-drop solution. PEO-PPO-PEO triblock 
copolymer was also used by two other studies. Liaw et al. developed eye drop solution containing the 
polymeric micelles of Pluronic F127 to deliver DNA plasmids for gene therapy in order to increase the 
stability of DNA plasmids in vivo.[72] More recently, Kadam et al. used the micellization of Pluronic 
F127 in aqueous environment to encapsulate anti-epileptic drug carbamezapine to increase the water 
solubility of the drug.[73] 
A stimuli-responsive micellar drug delivery system has also been developed. A triblock copolymer 
comprising N-isopropylacrylamide (NIPAAM), vinyl pyrrolidone (VP) and acrylic acid (AA) was 
cross-linked with N,N-methylene bis-acrylamide (MBA) to form NPs.[74] The micellar NPs were 
analyzed for the delivery of anti-inflammatory drug Ketorolac. The polymeric micellar system 
possesses a unique thermosensitivity since the lower critical solution temperature (LCST) of triblock 
copolymer was found near the physiological temperature. Therefore, the micellar system showed 
temperature-dependent release phenomena which can be utilized to control the release of the drugs to 
specific targeting tissues. 
Other types of block copolymers were also exploited by various research groups. Due to the small 
sizes and the stable suspension in aqueous environment, polymeric micelles have also been injected 
into the vitreous cavities using intravitreal delivery route. Roy et al. was able to demonstrate intravitreal 
delivery of antisense oligonucleotides to the retina of a rat using polyoxyethylene-polyspermine (PEO-
b-PSP) carrier to decrease the fibronectic expression in retinal vascular cells.[75] The block copolymer 
formed an effective diameter of 12 nm with the oligonucleotides embedded in the matrix. The NPs 
persisted up to 6 days in the retinal microvessels without showing any toxic effects after being delivered 
intravitreally. The study provided that the NP delivery method successfully reduced the expression of 
fibronectic mRNA level to 86.7% 2 days after injection, and down to 46.7% at day 6. An in vivo study 
carried out by Bourges et al. demonstrated that nanoparticles injected through intravitreal means 
showed tendency to migrate through the retinal layers and accumulate in RPE cells. They observed the 
presence of the nanoparticles in RPE cells up to 4 months after the initial single intravitreal injection, 
which provides a promising long term drug delivery tool to the posterior segment of the eye.[76]  
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Various types of amphiphilic copolymers have also demonstrated their ability to improve the in vivo 
bioavailability of the encapsulated drugs. Qu et al. synthesized chitosan-based amphiphilic copolymer, 
quaternary ammonium palmitoyl glycol chitosan (GCPQ).[77] The modified amphiphilic copolymer 
encapsulated hydrophobic drugs by forming micellar clusters, and showed encapsulation of up to 20 – 
200 times more hydrophobic drugs compared to that of Pluronic block copolymers. Upon both 
intravenous injection and topical ocular application of GCPQ with prednisolone, the bioavailability of 
prednisolone increased 10-fold compared to a commercial emulsion formulation of the same drug. Shen 
et al. utilized thiolated PEG stearate as a surfactant to modify the surface of nanostructured lipid carrier 
(NLC) in order to render mucoadhesiveness for the nano drug carriers.[3] The Mucoadhesion was 
achieved by the disulfide linkage between the thiol groups of the nanocarrier and the mucin particles 
(Figure 4). When topically administered to the rabbit eye, the thiolated NLC improved the drug 
concentration and the precorneal retention time of the encapsulated cyclosporine, which remained in 
the cul-de-sac for up to 6 h.  A number of studies have also focused on using prodrugs for enhanced 
penetration through ocular barriers.[78, 79] An amphiphilic prodrug of tilisolol, O-palmitoyl tilisolol, 
was developed by Kawakimi et al. in order to improve the ocular adsorption of the drug through 
cornea.[80] Upon topical instillation, the prodrug form of tilisolol showed prolonged retention and high 
drug concentration in both tear fluid and cornea compared to the tilisolol suspension. 
Micellar drug carriers have also shown increased ocular permeability of various drugs, when 
compared to their pure drug solution forms.[50, 81] From these studies, it is evident that polymeric 
micellar drug carriers have great potential not only in improving the drug stability and release 
mechanism to prolong the therapeutic activity of the encapsulated drugs, but they also  show promise 
in increasing the permeability of the drugs through various ocular barriers.  
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Figure 4. Schematic representation of the interaction between the thiolated NLCs and mucus 
(Reproduced with permission from [3]). 
2.6.2 Hydrogels 
Hydrogels are defined as water-soluble polymeric network that has the ability to absorb more than 20% 
of its weight of water and still main its 3D structure.[82] Hydrogels have been studied extensively in 
medicinal applications such as tissue engineering and drug delivery due to their unique properties.[83] 
The chemical and physical properties of hydrogels can be easily modified simply by changing choice 
of polymers since hydrogels can be fabricated from any hydrophilic polymer. Hydrogel networks are 
extensively studied as controlled and sustained drug delivery system since their porosity of the matrix 
can be tailored by modifying the crosslinking density, or using external stimuli such as pH or 
temperature, to control the diffusivity of the drugs in the matrix.  
Barbu et al. fabricated nanoparticulate hybrid polymeric hydrogels with size range from 10 to 70 nm 
to investigate their feasibility of employing different ophthalmic drugs.[84] The copolymers used for 
fabricating the nano-sized hydrogels combined chitosan or acrylic acid-functionalized chitosan which 
has been copolymerized with either 2-hydroxyethyl methacrylate (HEMA), or with N-
isopropylacrylamide (NIPAM) to impart thermosensitivity to the nanoparticulate system. Chitosan-
based nanomaterials have been widely studied for diverse applications in medicine due to its 
biocompatible, biodegradable, mucoadhesive and non-toxic properties.[85] Chitosan’s mucoadhesive 
property is especially important in topical ocular drug delivery system since it prolongs the retention 
of the delivery system on the mucus, which further increases the duration of drug activity. The in vitro 
drug release results demonstrated that the nanoparticulate system showed sustained-release phenomena 
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and the release rate of various drugs depended on the % content of chitosan materials in the hydrogels. 
More recent studies have focused on using in-situ gelation properties of some of the hydrogel materials 
in order to enhance the ocular bioavailability of the drugs and the in vivo drug activity. Pluronic F127, 
in addition to forming micellar structures due to its amphiphilic nature, has been used to fabricate 
hydrogel network system. Due to its temperature sensitive nature, Pluronic F127 was studied by 
different groups as an in-situ gelling agent for ocular delivery applications.[86, 87] The sol-gel 
transition temperature of Pluronic F127 was below the human physiological temperature of 37 °C. The 
property was utilized by preparing a liquid solution of Pluronic F127 with drugs of interest at low 
temperatures. Subsequently, upon administration into the physiological environment, the solution 
undergoes gelation to create a polymeric matrix where the drug is entrapped and released slowly 
through the gel by diffusion mechanism. 
2.6.3 Liposomes 
Liposomes are biocompatible and biodegradable particles consisting of membrane-like lipid bilayers 
composed mostly of phospholipids.[88] Formed by amphiphilic phospholipids, liposomes have hollow 
spherical structures (vesicles) with both lipophilic (lipid bilayer) and hydrophilic (aqueous 
compartment) phases. Due to this biphasic nature, liposomes can encapsulate both hydrophilic and/or 
lipophilic therapeutic agents in each of the compartment. The properties of liposomes, such as surface 
charge, can be tuned substantially by varying the lipid composition. Since the sialic acid moieties in 
the mucous membrane of the corneal surface is negatively charged, positively charged liposomes are 
preferentially captured at the corneal surface compared to neutral or negatively charged liposomes.[32] 
In addition, a recent study showed that positively charged liposomes also increased the extent of 
absorption of the encapsulated drugs across corneal membranes.[89] To achieve this characteristic, 
numerous studies have focused on coating the liposomal surface with mucoadhesive polymer chitosan. 
Diebold at el. investigated the cellular uptake effects of liposome-chitosan nanoparticle complexes 
(LCS-NP) in the precorneal moieties. Strong cellular uptake of LCS-NP in the conjunctiva and less 
intense uptake by corneal epithelium suggested that the NPs were first retained by mucus layer, and 
subsequently enter through the conjunctival cells. They also showed that ocular drug delivery system 
liposome-chitosan nanoparticle complexes (LCS-NP) showed negligible in vitro toxicity and 
acceptable in vivo tolerance.[90] Li et al. proposed using low molecular weight chitosan (LCH) coating 
on liposomes and investigated their in vitro and in vivo properties.[91] The coating of LCH not only 
modified the surface to have positive charge, which enhanced its interaction with the mucous membrane 
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of the corneal surface, but it also showed increased transcorneal penetration of the LCH coated 
liposomes. The effect of surface coating subsequently led to prolonged retention of the encapsulated 
drugs at the corneal surface, and also provided potential of using the liposomal carriers as transcorneal 
drug delivery system to increase bioavailability of the drugs in the aqueous compartment. However, 
chitosan has shown precipitation phenomena near physiological pH, and therefore, some studies used 
a modified version of chitosan to solve the precipitation issue. Wang et al. also explored using N-
trimethyl chitosan (TMC)-coated liposomes to delivery Coenzyme Q10 to the human lens epithelial 
cells to protect against oxidative damages.[92] Chitosan chains were modified to the quaternized 
derivative TMC in order to overcome issues such as precipitation of chitosan at neutral pH. The study 
also demonstrated that the TMC-coated liposomes exhibited excellent corneal permeation – increasing 
the permeability coefficient more than two times in comparison with values obtained from control 
study. 
Other studies have used different coating materials on the liposomes to achieve enhanced 
pharmacokinetic properties. Hosny developed ofloxacin encapsulated liposomes which were further 
incorporated into in situ thermosensitive hydrogel system composed of chitosan/β-glycerophosphate in 
order to enhance the transcorneal permeation of ofloxacin.[93] The liposomal hydrogel system 
improved the transcorneal permeability of ofloxacin sevenfold compared to that of the aqueous 
solution. In addition, the drug delivery system ensured steady and prolonged permeation of the drugs 
improving the bioavailability. Bochot et al. used PEG coating on the surface of liposomal formulation 
to sterically stabilize the liposomes. Intravitreal methods were used to inject the liposomal formulation 
into the vitreous humor, where the liposomes showed favored biodistribution at retina-choroid moieties 
compared with non-target tissues such as sclera or lens. The administration of liposome-encapsulated 
phosphodiester (16-mer oligothymidylate) oligonucleotides in the vitreous humor also showed 
sustained release phenomenon, which offers prospect that the liposomes can be used as intravitreal 
delivery system targeting retina and choroid where most of the ocular diseases occur. Hironaka et al. 
studied the effect of size and rigidity of the liposomes on the delivery performance of the liposomes to 
the posterior segment of the eye.[94] It was shown that rigid liposomes with size ranges in the nano-
scale showed potential as ocular delivery system targeting the posterior segment of the eye.  
Despite the recent advancement of using liposomal formulations for ocular drug delivery showing 
improvements in precorneal retention, sustained drug release and transcorneal permeation, liposomes 
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still face challenges in their limited long term structural stability and drug loading capacity due to the  
inherent complex nature of their structures.  
2.6.4 Niosomes 
Niosomes, a type of liposomes, are comprised of amphiphilic non-ionic surfactants to form vesicle 
structures. Niosomes, like liposomes, can entrap both hydrophilic and hydrophobic drugs. Niosomes 
are generally preferred over other vesicular systems as topical ocular drug delivery systems due to 
several reasons: they are chemically more stable, less toxic because of the non-ionic nature of the 
surfactants, easier to handle without special precautions, able to improve the performance of the drug 
via better bioavailability and controlled delivery at a specific site, and they are also biodegradable, 
biocompatible, and non-immunogenic.[95, 96]  
Abdelbary et al. investigated niosomes as potential topic ocular drug delivery system for local 
antibiotic gentamicin.[95] The in vitro results showed that the encapsulation efficiency were as high as 
92%, and the encapsulation of gentamicin showed prolonged release compared to the control study. 
The encapsulation efficiency and the release rate varied depending on the cholesterol content, the type 
of surfactant used, and the presence of charge inducer dicetyl phosphate. Ocular irritancy test of 
niosomes also showed no sign of redness, inflammation or increased tear production, indicating that 
the niosomes can be used as enhanced and safe topical ocular drug delivery system. Prabhu et al. studied 
the feasibility of vesicular formulation, using both liposome and noisome, as drug delivery system for 
brimonidine tartrate in order to improve its intraocular pressure (IOP) lowering activity for treatment 
of glaucoma.[97] The vesicle formulations were in the size range of 210-245 nm, with drug payload up 
to 42 w/w%. Although the vesicular formulations did not show as high of IOP-lowering activity as that 
of marked formulation of pure drug solution, they extended the duration of the activity up to 6 to 8 fold 
compared to the marketed formulation. Niosomes coated with mucoadhesive materials, chitosan, were 
developed by Kaur at el. to investigate its potential as drug delivery system for timolol maleate (TM), 
which is another treatment drug for glaucoma having IOP lowering effect.[98] The chitosan coated 
noisome showed higher and prolonged corneal permeation of TM into the aqueous humor compared to 
the pure drug solution. Consequently, the IOP lowering effect of the niosomal formulation of TM was 
maintained up to 8 hrs, compared to 1.5 hrs of the drug solution. 
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2.6.5 Dendrimers 
Dendrimers are three-dimensional, highly branched, and tree-structured macromolecules. Dendrimers 
have nanoscale sizes due to their well-organized synthesis strategy. In addition, because of their highly 
branched structure, the surface of the dendritic macromolecules can be easily functionalized with 
desired properties. Dendrimers can also encapsulate hydrophobic drug molecules since they possess 
internal empty cavities and open conformations for low generation dendrimers. Due to these properties, 
dendrimers are very attractive system for drug delivery applications.[99]  
One of the most widely studied dendrimer for ocular drug delivery system is poly(amidoamine) 
(PAMAM).  Vandamme and Brobeck used PAMAM dendrimers to improve ocular residence time.[56] 
They have demonstrated that the use of 0.25 w/v% PANAM solution mixture with pilocarpine 
prolonged ocular residence time of pilocarpine up to 5 hours, which is comparable to Carbopol® (a 
commercial bioadhesive polymer for ophthalmic dosage forms) but without causing the irritation that 
was observed in Carbopol® administration. The study also showed that residence time was longer for 
dendrimers with hydroxyl or carboxyl surface groups. Puerarin-PAMAM complexes were developed 
by Yao et al. through hydrogen-bond interactions.[100] Similar to the previous study, they have 
demonstrated prolonged ocular residence time of the puerarin by having the complex formulation, 
compared to puerarin eye drops. It was also reported that, although the puerarin-PAMAM complex did 
not increase the corneal permeability coefficient, the physical mixture of cationic G4 PAMAM 
dendrimer with puerarin was found to have enhanced corneal permeability coefficient and increased 
cumulative amount of puerarin permeating across the cornea.  Durairaj et al. used complex formation 
between dendrimeric polyguanidilyated translocators (DPTs) and gatifloxacin (GFX) antibiotic to 
improve the permeation across sclera-choroid-retinal pigment epithelium (SCRPE) membranes.[101] 
The complex improved the permeation of GFX across SCRPE 40% in 6 hours. In vivo studies showed 
that the topical administration of the complex was able to maintain higher drug concentration for up to 
24 hours, compared to pure drug solution. New phosphorus-containing dendrimers, with quaternary 
ammonium salt as core and carboxylic acid terminal groups have been synthesized.[57] These cationic 
dendrimers were able to physically associate with amino groups of carteolol (an ocular anti-
hypertensive drug) by forming ion pairs. The generation 2 dendrimer-carteolol formulation improved 
the corneal penetration 2.5 times compared to carteolol alone. However, the generation 2 dendrimer 
showed poor water solubility and therefore the amount of instilled carteolol was limited. 
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The ease of surface functionalization and the ability to encapsulate hydrophobic drugs render 
dendrimers an attractive ocular drug delivery system.  In some animal studies however, vision blurring 
effect was observed after the administration of dendrimer on the ocular surface.[14] This issue must be 
addressed in the future studies using dendrimers before proceeding to clinical trial studies. 
2.6.6 Cyclodextrins 
Cyclodextrins (CDs) are a family of cyclic oligosaccharides, composed of 6 to 8 glucose units which 
have been shown to improve pharmacokinetic properties of many drugs through formation of inclusion 
complex.[102] The application of cyclodextrins in ophthalmic formulations has been reviewed 
extensively in the past decade.[102-104] The complex inclusion of hydrophobic drugs with CDs can 
increase the aqueous solubility of those drugs. Toxicity studies in the past have shown that orally 
administered CDs are practically non-toxic, due to the lack of absorption from gastrointestinal 
tract.[105] One of the most extensively reported cyclodextrin used as ocular drug delivery enhancement 
is 2-hydroxypropyl β-CD (HPβCD) which is modified with hydroxylpropyl derivative to increase its 
water solubility. Topical administration of CDs have also shown no toxic effects, and eye drop solutions 
containing 45% of HPβCD showed no irritation effects in rabbits.[106] Similar to other types of 
nanomaterials described in this report, CDs also act as a permeation enhancer at biological barriers, 
such as cornea, by increasing the drug retention at the surface of the corneal epithelium.  
Wang et al. used inclusion complex between disulfiram (DSF) and HPβCD in eye drop formulation in 
order to increase the bioavailability of the drug across the corneal membrane.[107] Along with the 
addition of penetration enhancer hydroxypropylmethylcellulose (HPMC), the eye drop formulation 
successfully suppressed the cataract effect (i.e. lens opacity) for up to 48 hours in rabbits. Similarly, 
Zhang et al. also used HPβCD with complex inclusion of ketoconazole (KET) in topical eye drop 
formulation.[108] The incorporation of HPβCD increased the aqueous solubility of KET. Compared to 
the KET suspension, the HPβCD/KET complex significantly increased the bioavailability of KET; over 
8-fold in aqueous humor, and 12-fold in cornea.  More recently, another group has investigated the 
complex between HPβCD and indomethacin and found delayed release and high drug stability 
effect.[109] While showing no signs of irritation after administration to rabbits, HPβCD-indomethacin 
complex showed significant improvement in therapeutic efficacy in healing corneal wounds. Mahmoud 
et al. developed ionically crosslinked chitosan/sulfobutylether-β-cyclodextrin nanoparticles as ocular 
drug delivery system.[110] The nanoparticle system showed sustained release behavior of encapsulated 
econazole nitrate. Furthermore, the incorporation of chitosan on the surface of the nanoparticles also 
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significantly improved the ocular mucoadhesiveness which enable the nanoparticle as promising carrier 
for controlled ocular drug delivery system. 
2.7 Future perspectives 
The ﬁeld of ocular drug delivery has taken a signiﬁcant stride forward with the advent of 
nanotechnology. Numerous recent studies have focused on using various types of nanomaterials, such 
as polymeric micelles, hydrogels, liposomes, niosomes, dendrimers, and CDs as drug carriers, to 
increase the ocular bioavailability of various therapeutic agents. Topical administration of the drugs 
associated with the nanomaterials showed sustained release of the drug which increased the duration of 
therapeutic activity, consequently reducing the need for frequent administration. To date, 
demonstrating an enhancement in the extent of absorption into the vitreous cavity across corneal 
membranes, the topical administration of nanomaterial/drug complexes to target the posterior segment 
of the eye has yet to be proven to be therapeutically effective compared to intravitreal or periocular 
injections. However, due to the invasive nature of intravitreal and periocular injections, further studies 
utilizing nanomaterials to overcome the various ocular barriers are expected. Although several in vivo 
studies have shown that the nanodrug carriers did not induce any signs of irritation or inﬂammatory 
responses, the long-term effect of these nanomaterials in both the ocular region and the systemic 
circulation must be rigorously analyzed. There is no doubt that pharmaceutical researchers will continue 
improving the performance of ocular drug delivery systems with the help of nanotechnology, to achieve 
therapeutically effective, patient-compliant, and low cost systems with negligible side-effects. 
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Chapter 3 
Development of nanoparticle drug carriers using PLA-Dex block 
copolymers 
3.1 Summary 
NP drug delivery carriers formed by the self-assembly process of linear block copolymer PLA-Dex 
have been developed. The characterization of the NPs formed by the self-assembly process of PLA-
Dex showed some unique properties that are desirable for drug delivery system. The NPs sizes were 
tuneable from 15 to 70 nm simply by changing the molecular weights of the PLA and/or Dextran used. 
In addition to the abundant functional hydroxyl groups on the Dextran surface, the high surface area-
to-volume ratio provides effective surface functionalization for targeted therapy. The NPs were also 
able to encapsulate large dose of hydrophobic therapeutic agent, Doxorubicin, and showed sustained 
release phenomenon for up to 8 days. These results demonstrate that PLA-Dex is a promising new 
biomaterial for drug delivery purposes, which can be further explored as a topical ocular drug delivery 
system for targeted therapy through surface functionalization with specific targeting ligands. 
3.2 Introduction 
Nanomedicine – the fusion of nanotechnology and medicine – is one of the most promising approaches 
to address challenges associated with conventional drug delivery methods [111]. In the past decade, 
drug delivery systems constructed from polymeric nanoparticles (NPs) have been the cornerstone of 
progress in the field of nanomedicine [61, 112, 113]. Various types of polymeric materials composed 
of poly(D,L-lactide) (PLA), poly(glycolide) (PGA), poly(lactide-co-glycolide) (PLGA), and poly(ε-
caprolactone) (PCL), have been studied extensively for NP drug delivery applications [38, 114, 114]. 
To date, masking the NP surface with poly(ethylene glycol) (PEG) has been the most effective strategy 
to improve the stabilities of NP drug delivery systems in vitro and in vivo [115-121]. PEGylated NPs 
with sizes under 70 nm in diameter have the potential of bypassing the reticuloendothelial system 
(RES), which leads to prolonged circulation half-life of the particles [122]. Particles with size smaller 
than 100 nm preferentially accumulate at the tumor site by enhanced permeation and retention (EPR) 
effect and also evade the organs of the RES [123]. Once the NPs reach the intended tumor site, the rate 
of NP uptake by the tumor cells is largely influenced by the particle size. It has been demonstrated that 
rapid cellular uptake of NPs can be achieved when particle size falls below 50 nm [124]. PLGA-PEG 
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is the most widely used polymer for making biodegradable drug delivery system. However, the self-
assembly of PLGA-PEG block copolymer generally yields NPs of sizes greater than 150 nm [125]. 
Although smaller particles can be synthesized, they suffer from low drug encapsulation and rapid drug 
release [125]. An emerging strategy for making PLGA-PEG NPs under 100 nm is by rapidly mixing 
the block copolymers in a microfluidics device [125]. 
Here, we synthesized a linear block copolymer using PLA and Dextran (Dex-b-PLA), and 
demonstrated that NPs composed of Dex-b-PLA can self-assemble into core-shell structured NPs with 
sizes less than 40 nm without using any flow-focusing devices. We further showed the size of Dex-b-
PLA NPs can be precisely fine-tuned between 15-70 nm by altering the MW of the compositional 
blocks. Dextran, a natural polysaccharide composed of 1→6 linked α-D-glucopyranosyl units, was 
selected as a model hydrophilic block because of its high hydrophilicity and biocompatibility. Studies 
have shown that Dextran coated NPs showed superior colloidal stability compared to those coated with 
PEG chain [126]. Dextran and PLA have been explored together in the synthesis of PLA-graft-Dex 
[127]. However, Dextran-grafted copolymer has a major limitation because grafting density (i.e. the 
number of PLA per Dextran backbone) is difficult to control, and the grafting is limited only to low 
MW PLA as opposed to high MW PLA. In this study, linear block copolymers composed Dextran and 
PLA were synthesized, and the size and morphologies of the NPs formed from Dex-b-PLA were 
systematically controlled by varying their composition.  The drug encapsulation efficiencies of the NPs 
and their release kinetics were also evaluated using Doxorubicin as a model hydrophobic anti-cancer 
drug. The hemolytic activity of the NPs was tested to profile the biocompatibility of the NPs in systemic 
circulation, and the blood circulation half-life and biodistribution of the NPs in rats were assessed. 
3.3 Experimental Section 
3.3.1 Materials 
Acid-terminated poly(D,L-lactide) (PLA, Mw ~ 10, 20 and 50 kDa) and PLGA-PEG (PLGA Mw ~ 40 
kDa, PEG Mw ~ 6 kDa) were purchased from Lakeshore Biomaterials (Birmingham, AL, USA). PLA 
was purified by dissolving in dimethyl sulfoxide (DMSO) and precipitating in methanol to remove 
residual monomers. Dextran (Dex, Mr ~ 1.5, 6, and 10 kDa), hydrochloric acid (HCl), triethylamine 
(TEA), N-(3-dimethylaminopropyl)-N-ethylcarbodiimide (EDC), and sodium cyanoborohydride 
(NaCNBH3) were purchased from Sigma Aldrich (Oakville, ON, Canada), and used without further 
purification. N-Hydroxysulfosuccinimide (Sulfo-NHS) and N-Boc-ethylenediamine were purchased 
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from CNH Technologies (Massachusetts, USA). Doxorubicin-HCl (MW = 580 Da, Intatrade GmBH, 
Bitterfield, Germany) was deprotonated by adding TEA (2M equivalent) in the aqueous solution of 
Doxorubicin-HCl, and the hydrophobic form of Doxorubicin was extracted using Dichloromethane 
(DCM).[128] Borate buffer was prepared at a concentration of 0.05M with pH of 8.2 by mixing boric 
acid and sodium hydroxide. Whole sheep blood (in Alsever’s) was purchased from Cedarlane 
(Burlington, ON, Canada). Veronal Buffer solution (VBS, 5x) was purchased from Lonza Walkersville 
Inc (Walkersville, MD, USA). Tritium [3H]-PLA-radiolabeled nanocrystals were purchased from 
PerkinElmer (Boston, MA, USA). 
3.3.2 Synthesis of PLA-Dex block copolymer 
The synthesis of the linear block copolymer was divided into three stages: 1) reductive amination 
between Dextran and N-Boc-ethylenediamine, 2) deprotection of the Boc group, and 3) conjugation of 
the end modified Dextran with PLA (Figure 5). The first step of the synthesis involves reductive 
amination between the aldehyde on the reducing end of Dextran and the amine group of N-Boc-
ethylenediamine cross-linker. In a typical reaction, Dex6 (Mr ~6 kDa, 6 g) was dissolved in 15 mL of 
borate buffer (0.05 M, pH 8.2) with excess N-Boc-ethylenediamine. The reducing agent, NaCNBH3 (1 
g, 15 mmol), was added to the borate buffer solution and the mixture was stirred for 72 hours in dark 
conditions at room temperature. The mixture was then washed in methanol to remove any unreacted 
molecules or catalysts. The end-modified Dextran was dried overnight in vacuo and re-dissolved in de-
ionized water (DI-H2O). The deprotection of Boc group was performed first by adding HCl (~ 4 M) for 
1 hour to cleave the amide bond between the Boc group and the protected amine moiety. Subsequently, 
TEA was added to increase the pH of the solution up to 9 to deprotonate the NH3+ end groups which 
were deprotected. The mixture was then washed twice using methanol and dried in vacuo. The amine 
terminated Dextran and carboxyl terminated PLA20 (Mw~ 20 kDa, 6 g, 0.3 mmol) were dissolved in 
DMSO.  The conjugation between the two polymers was facilitated by adding catalysts EDC (120 mg, 
0.773 mmol) and Sulfo-NHS (300 mg, 1.38 mmol) and allowing reaction to proceed for 4 hours at room 
temperature. The resulting Dex-b-PLA was twice precipitated and purified using excess methanol. In 
order to remove free Dextran, the mixture was dissolved in acetone (30 mL) to form a cloudy 
suspension.  This was centrifuged at 4000 rpm for 10 minutes and the supernatant was extracted 
carefully. The supernatant was purged with air to remove the solvent and then dried overnight in vacuo 
to obtain the final copolymers. The three stages of the synthesis were verified by 1H NMR 
characterization. 
  27 
 
Figure 5. Synthesis of Dex-b-PLA block copolymers. a) Synthesis of Dextran-NH-Et-NH-Boc. 
Conditions: NaCNBH3 in Borate buffer (pH 8.2) for 72 hr at RT in dark. b): Synthesis of 
Dextran-NH-Et-NH2. Conditions: HCl/TEA in DI-H2O for 1hr each at RT. c): Synthesis of 
Dextran-NH-Et-NH-PLA. Conditions: EDC/Sulfo-NHS RT for 4hrs. 
3.3.3 Characterization of PLA-Dex NPs 
The PLA-Dex NPs were prepared using a nanoprecipitation method: 1mL of Dex-b-PLA in DMSO (10 
mg/mL) was added in a drop-wise manner to 10 mL of DI-H2O under constant stirring in order to form 
NPs. This was stirred for 30 minutes. The sizes of the NPs were analyzed using 90Plus Particle Size 
Analyzer (Brookhaven, λ = 659 nm at 90°). The volume averaged multimode size distribution (MSD) 
mean diameters were used from the results. The particle size and the morphology of the Dex-b-PLA 
NPs were further verified using Transmission Electron Microscopy (TEM, Philips CM10). 
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3.3.4 Doxorubicin encapsulation in PLA-Dex NPs 
The encapsulation of Doxorubicin in the Dex-b-PLA NPs was accomplished using a nanoprecipitation 
method. Dex-b-PLA and Doxorubicin were both dissolved in DMSO (Dex-b-PLA concentration of 7 
mg/mL, with varying drug concentrations). 1 mL of the DMSO solution was added drop-wise into 10 
mL of water under stirring and stirring was continued for additional 30 minutes. The NPs in water were 
filtered through a syringe filter (pore size = 200 nm) to remove the drug aggregates and subsequently 
filtered through Amicon filtration tubes (MWCO = 10 kDa, Millipore) to further remove any remaining 
free drugs in the suspension. The filtered NPs containing encapsulated Doxorubicin were resuspended 
and diluted in DMSO. Consequently, the drug loading (wt%) in the polymer matrix was calculated by 
measuring concentration of the Doxorubicin in the mixture by obtaining the absorbance of the solution 
at 480 nm using Epoch Multi-Volume Spectrophotometer System (Biotek). The measurements were 
obtained in triplicate (n = 3, mean ± S.D). The absorbance measured from the same procedure using 
the polymers without the drugs was used as the baseline. The absorbance was correlated with the 
concentration of the Doxorubicin in DMSO by using standard calibration obtained. The same procedure 
was used for PLGA-PEG to encapsulate Doxorubicin for comparative analysis. 
3.3.5 In vitro release of Doxorubicin from PLA-Dex NPs 
Using the procedure described in the previous section, drug encapsulated NPs were prepared and 
filtered to remove non-encapsulated drug aggregates.  A purified sample of NPs-drug suspension was 
collected to measure the maximum absorbance and this was used as the 100% release point. 
Subsequently, the NP-drug suspension was injected into a Slide-a-Lyzer Dialysis cassette (MWCO = 
20 kDa, Fisher Scientific) and dialyzed against 200 mL of phosphate buffered saline (PBS, pH 7.4) at 
37 °C under mild stirring. At predetermined time intervals, 1 mL of the release medium was extracted 
and the same volume of fresh new PBS was added to the release medium. The extracted release medium 
was used to perform UV-Vis absorption measurements at 480 nm in triplicates (n = 3, mean ± S.D). 
The release medium was replaced several times to maintain the concentration of Doxorubicin in the 
medium below 3 µg/mL and to stay below the solubility limit of the Doxorubicin in PBS. The release 
of Doxorubicin from PLGA-PEG was also obtained with identical procedure for comparative analysis. 
All experiments were performed in dark environment, and the beakers were sealed with Parafilm to 
prevent evaporation of PBS.  
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3.4 Results and Discussion 
3.4.1 H NMR characterization of PLA-Dex 
The three steps of the synthesis were verified using Proton Nuclear Magnetic Resonance (1H NMR, 
300 MHz) spectroscopy. The conjugation of Dextran with N-Boc-ethylenediamine was confirmed by 
the presence of multiplets at 1.3 ppm corresponding to the Boc group (Figure 6, II), which then 
disappears in the deprotection step (Figure 6, III). The last step, the conjugation between Dextran and 
PLA, was demonstrated by showing both peaks corresponding to the monomers of Dextran (multiplets 
at 4.86ppm) and PLA (multiplets at 5.2 ppm).  
 
Figure 6.  1H NMR of I. Dextran (10 kDa), II. Dextran-Ethylenediamine-Boc, III. Dextran-
Ethylenediamine, IV. PLA (20 kDa), V. PLA-Dex (PLA20-Dex10).[4] 
3.4.2 Size and morphology of the PLA-Dex NPs 
It is hypothesized that, due to their amphiphilic nature, PLA-Dex block copolymers undergo self-
assembly process to form nanoparticles with micellar structure. In aqueous medium, the hydrophobic 
PLA chains form the core of the nanoparticles while the hydrophilic Dextran form the shell of the 
nanoparticles, shielding PLA core from the surrounding water. It was shown that varying the molecular 
weights (MW) of PLA and/or Dextran affected the particle sizes formed by the NPs (Figure 7a). 
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Increasing the MW of PLA increased the NP size since larger core was formed by higher MW of PLA's. 
On the other hand, increasing the MW of Dextran decreased the NP size since longer Dextran was more 
flexible and therefore able to "fold-down" on the particle surface, resulting in smaller hydrodynamic 
diameters.[129] Transmission Electron Microscopy (TEM) images further verified the sizes and the 
micellar morphologies of the PLA-Dex NPs (Figure 7b). 
 
Figure 7. Particle size and morphology of PLA-Dex NPs: a) Effect of MW's of PLA and 
Dextran on the sizes of the NPs formed from nine different polymers; b) TEM image of PLA20-
Dex6 (MWPLA = 20 kDa, MWDEX = 6 kDa).[4] 
3.4.3 Drug encapsulation and release  
The ability of the NPs to encapsulate hydrophobic drugs and release them in a sustained manner were 
also studied. Using anticancer drug Doxorubicin as a model hydrophobic drug, PLA20-Dex6 and 
PLA20-Dex10 were selected for the study and were also compared with the commercially available 
biomaterial Poly(lactic-co-glycolic acid)-b-Poly(ethylene glycol). The PLA-Dex NPs showed 
maximum drug loading of 21.2 wt% (PLA20-Dex10), whereas PLGA-PEG NPs showed maximum 
loading of 7.1 wt% (Figure 8). The maximum loading of PLA-Dex NPs are also comparable to that 
commercially available liposomal formulation Doxil®. In in vitro Doxorubicin study, both PLA-Dex NPs 
and PLGA-PEG NPs showed initial burst release region followed by a sustained release region. The 
initial burst release region is due to the release of Doxorubicin that is either in the free suspension or 
loosely bound near the surface of the NPs. On the other hand, the sustained release region is associated 
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with the diffusion of Doxorubicin that is encapsulated in the PLA core of the NPs. PLGA-PEG NPs 
exhibited burst release for the first 6 hours of the study followed by a sustained release for up to 4 days, 
whereas both type of PLA-Dex NPs showed 24 hours of burst release and subsequent sustained release 
region lasted up to 8 days.  
One of the main reasons that PLA-Dex NPs showed more desirable drug encapsulation and release 
phenomenon compared to PLGA-PEG is hypothesized to be due to the greater hydrophilicity of 
Dextran over PEG chains. Having greater hydrophilicity than PEG chains, Dextran chains have less 
chance of being randomly associated with the PLA core of the NPs, thus improving the association of 
hydrophobic drug with the hydrophobic PLA core. This phenomenon may explain the increased drug 
loading in PLA-Dex NPs as opposed to PLGA-PEG NPs, which also increase the amount of drug that 
slowly diffuse from the core of the PLA thus prolonging the duration of sustained release region. 
 
Figure 8. Drug encapsulation and release: Doxorubicin loading in PLA-Dex and PLGA-PEG 
NPs (left), and Doxorubicin in vitro release profiles (right).[4] 
3.5 Conclusion 
A linear block copolymer of Dextran and PLA was synthesized and used for making size tuneable NPs. 
The size of NPs was controlled under 50 nm, simply by modulating the MW of Dextran and PLA. 
These NPs demonstrated efficient doxorubicin encapsulation, and controlled drug release. These NPs 
have provided us with promising tools for developing a controlled drug delivery system for 
nanomedicine applications. 
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Chapter 4 
Mucoadhesive nanoparticles for topical ocular drug delivery 
4.1 Summary 
Mucoadhesive NP drug carriers have attracted substantial interest as a potential solution to the low 
bioavailability of topical formulations. In this study, NPs composed of PLA-Dex and surface 
functionalized with PBA were developed as mucoadhesive NP drug carriers. The NPs encapsulated up 
to 13.7 wt% Cyclosporine A and exhibited sustained drug release for up to 5 days in vitro at a clinically 
relevant dose. High densities of PBA functionalization were achieved due to the abundance of 
functional groups on dextran surfaces, and 23 mol% or more functionalization facilitated the mucin-
NP interaction in in vitro analysis. These data show that PLA-Dex_PBA NP is a promising new 
biomaterial to significantly improve the bioavailability of topical formulations. 
4.2 Introduction 
Topical administration is the most common delivery method employed to treat corneal diseases. 
Common topical formulations, such as eye drops or ointments, suffer from low ocular bioavailability 
due to rapid drainage through the naso-lacrimal duct, nearly constant dilution by tear turnover, and low 
drug permeability across the corneal epithelium[6]. As a result, topical formulations are normally 
administered multiple times daily in order to achieve therapeutic efficacy, resulting in a higher potential 
for side effects and lower patient compliance. 
Recently, formulations using NPs as drug carriers have been proposed to overcome the limitations 
associated with topical administration methods. NP carriers have been shown to improve drug stability 
in water and also prolong drug activity through the controlled release of encapsulated compounds[1, 6, 
12, 35]. NPs formulated using biodegradable polymers, such as poly(lactic-co-glycolic acid) (PLGA), 
have been tested for ocular topical drug delivery applications[1, 7, 9, 33]. Poly(ethylene glycol)-based 
NPs, or PEGylated NPs, have attracted significant attention due to their ability to improve the stability 
of drug carrier systems in physiological environments[115, 119, 130, 131]. In chapter 3, we synthesized 
a dextran-based amphiphilic block copolymer, poly(D,L-lactide)-b-dextran (PLA-Dex), that can self-
assemble to form core-shell structured NPs. The size of PLA-Dex NPs can be precisely tuned between 
20 to 60 nm in diameter by simply adjusting the molecular weight of the two polymer chains[4]. 
Dextran has an abundance of functional hydroxyl groups on its back bone, as opposed to PEG, which 
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has one free functional group per chain. The higher density of surface functional groups can improve 
the efficiency of surface functionalization, and thus, desirable surface properties are more easily 
achieved with dextran based NPs. Moreover, dextran coated NPs showed excellent colloidal stability 
in physiological media in vitro and long retention in the systemic circulation in vivo [4, 132]. We 
postulate that the abundance of functional groups on dextran can be modified to target the ocular 
surface, and thus prolong corneal retention. 
The surfaces of polymeric NPs have been functionalized with molecular ligands that can selectively 
bind to the ocular mucosa to increase precorneal drug retention [133-136]. To date, the most widely 
used method to achieve mucoadhesion exploits electrostatic interactions between the negatively 
charged sialic acid residues of the corneal mucin and cationic polymers such as chitosan [134, 136]. 
However, the electrostatic interactions may be hindered by various counter ions in the tear fluid, 
resulting in the clearance of these NPs by tear turnover. The use of covalent binding via specific 
targeting ligands can further strengthen the mucoadhesive in order to improve corneal retention of the 
NPs. Phenylboronic acid (PBA), which contains a phenyl substituent and two hydroxyl groups attached 
to boron, can form a complex with the diol groups of sialic acid at physiological pH[137-142]. 
In this study, we aimed to functionalize PLA-Dex NP surfaces with PBA molecules for specific 
targeting of sialic acid residues of the ocular mucosa. The amount of PBA functionalization on the 
dextran surface can be varied to analyze its effect on the size of the NPs formed and the extent of their 
interaction with mucin particles in order to find the optimal formulation at which desirable 
mucoadhesion is achieved, without compromising the colloidal stability of the NPs formed. 
Cyclosporine A (CycA), which is prescribed for chronic dry eye syndrome [143, 144], was used as a 
model hydrophobic drug. The CycA encapsulation and release kinetics were evaluated in vitro. 
4.3 Experimental Section 
4.3.1 Materials 
Acid-terminated poly(D,L-lactide) (Mw ~ 20 kDa) was purchased from Lakeshore Biomaterials 
(Birmingham, USA) and washed with methanol to remove monomer impurities. Dextran (Mr ~ 10 
kDa), Cyclosporine A (CycA), 3-Aminophenylboronic acid monohydrate (PBA), sodium periodate 
(NaIO4), glycerol, and sodium cyanoborohydride (NaCNBH3) were purchased from Sigma Aldrich 
(Oakville, Canada). Simulated tear fluid (STF) was prepared for the in vitro release experiment using 
previously known formulation[145]  
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4.3.2 Surface functionalization of PLA-Dex NPs with PBA 
The synthesis of dextran-b-Poly(D,L-lactide) (PLA-Dex) was described in Chapter 3 [4]. PLA-Dex was 
dissolved in DMSO (30 mg/ml), and added slowly into water under mild stirring. Periodate oxidation 
of the dextran surface was carried out by adding 60 mg of NaIO4 and stirring for an hour. Subsequently, 
glycerol was added to quench the unreacted NaIO4. Various amounts of PBA (i.e. 40 mg for PLA-
Dex_40PBA) was added to the mixture along with NaCNBH3 for 24 hours. All reactions were carried 
out in dark. The mixture was then dialyzed in H2O for 24 hrs to remove any unreacted solutes, changing 
the wash medium 4 times.  
4.3.3 Characterization of PLA-Dex_PBA 
PLA-Dex_PBA was analyzed using 1H NMR (Bruker 300 MHz) using DMSO-d6 as the solvent. The 
amount of PBA attached to the dextran chain was quantified using UV-Vis absorption at 291 nm after 
performing the standard calibration of PBA in DMSO. PLA-Dex polymer in DMSO was used as the 
baseline. The sizes of the NPs were determined using dynamic light scattering (DLS) by measuring the 
multimode-size distribution (MSD) volume-average mean diameters. The sizes and morphology were 
further confirmed using transmission electron microscopy (TEM) by drying a sample of NP suspension 
on a copper grid and using phosphotungstic acid solution as the negative stain [4]. 
4.3.4 Cyclosporine A encapsulation and in vitro release 
The determination of encapsulation of CycA in PLA-Dex and PLA-Dex_PBA NPs was accomplished 
using methods described previously [4]. Both PLA-Dex and PLA-Dex_PBA NPs were also used in in 
vitro release study. 10 ml of NP-drug suspension was dialyzed against 200 mL of STF, with 0.1 w/v% 
sodium dodecyl sulfate, at 35 °C under stirring. At predetermined time intervals, 1 mL of the release 
medium was extracted and same volume of fresh STF was added to the medium. The amount of CycA 
was quantified using high-performance liquid chromatography (HPLC) equipment. 
4.3.5 In vitro mucoadhesion 
Mucoadhesion was calculated as the amount of mucin adsorbed per mg of NPs. NP suspension (1ml) 
was mixed with 1ml of mucin solution (1mg/ml in STF) and incubated at 37°C for 1 hr. The mixture 
was then centrifuged at 15,000 rpm for 1 hr and free mucin in the supernatant was quantified using the 
periodic acid/Schiff (PAS) staining method [146]. Mucin adsorption was calculated by subtracting the 
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free mucin concentration from the initial mucin concentration. Mucin standards (0.1, 0.25 and 0.5 
mg/ml) were determined using the same procedure to obtain a calibration curve.  
4.4 Results and Discussion 
4.4.1 Synthesis and characterization of PBA functionalized PLA-Dex NPs 
The 1H NMR spectrum of PLA-Dex_PBA shows peaks corresponding to both PLA (multiplets at 5.2 
ppm) and dextran (multiplets at 4.86 ppm), while also showing multiplet peaks at 6.6 ppm and 6.9 ppm 
which correspond to carbons from position 2 to 6 in the phenyl group of the PBA (Figure 9). UV 
absorption at 291 nm was measured to quantify the amount of PBA on the NPs with respect to the 
dextran monomers. Increasing the amount of PBA in the initial reaction mixture proportionally 
increased the final PBA conjugation on the dextran surface (Table 2), with highest density of 34.6 mol% 
(equivalent of about 3.5 PBA conjugated per 10 dextran monomers) achieved for PLA-Dex_320PBA 
NPs.  
 
Figure 9. 1H NMR characterization of PLA-Dex_PBA. 
Upon formation of NPs using nanoprecipitation method, the size and morphology of the PLA-
Dex_PBA NPs were characterized using DLS and TEM respectively. The sizes of the NPs were in the 
range of 25 to 28 nm, which are smaller than the unmodified NPs of 47.9 nm (Table 2). We postulate 
that the particle size reduction is attributed by the PBA molecules causing dextran chains to be less 
hydrophilic, leading to form more compact shells around PLA particle core. TEM images confirmed 
spherical morphology due to the formation of core-shell structure of the amphiphilic block copolymers 
(Figure 10). The sizes of PLA-Dex_PBA NPs obtained are smaller compared to what can normally be 
achieved with PEG based block copolymers such as PLGA-PEG[125]. We postulate that smaller NPs 
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may be more desirable for mucoadhesion since they provide greater surface area for interaction mucous 
membrane.  
 
Figure 10. TEM imaging of PLA-Dex_320PBA NPs. 
 
Table 2. PBA conjugation efficiency and mucin adsorption of  PLA-Dex NPs. 
Formulation PBA:Dexa) 
(mol%) 
Diameterb) 
(nm) 
Mucin adsorbed/mg of 
NPs (mg) 
PLGA-PEG 0 133.9 ± 6.1 0.177 ± 0.004 
PLA-Dex 0 47.9 ± 0.5 0.452 ± 0.007 
PLA-Dex_10PBA 2.85 ± 0.03 27.5 ± 0.9 0.575 ± 0.028 
PLA-Dex_40PBA 12.2 ± 0.2 26.7 ± 0.1 0.584 ± 0.026 
PLA-Dex_160PBA 22.9 ± 0.3 25.2 ± 1.0 0.604 ± 0.016 
PLA-Dex_320PBA 34.6 ± 0.2 28.1 ± 0.3 0.471 ± 0.009 
a)Mol% of PBA with respect to dextran monomers; b)NP diameter was determined from DLS 
4.4.2 Cyclosporine A encapsulation and in vitro release 
The encapsulation of CycA was accomplished through the nanoprecipitation method. Maximum 
encapsulation of CycA was achieved at initial feed of 40 wt%: PLA-Dex NPs encapsulated up to 10.8 
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wt% whereas PLA-Dex_40PBA and PLA-Dex_320PBA encapsulated up to 11.2 and 13.7 wt% 
respectively (Figure 11a). The 13.7 wt% encapsulation is equivalent of 2.38 µg of CycA in 28 µL 
formulation (same as the administration volume of commercially available RESTASIS®), whereas the 
commercial product contains 14 µg. Therefore, a therapeutically relevant dosage can be achieved by 
simply adjusting the polymer and drug concentration in the formulation. One possibility that PLA-
Dex_PBA NPs encapsulated higher amount of CycA compared to PLA-Dex NPs is that the more 
hydrophobic dextran chains, due to the PBA conjugation may be able to trap more CycA near the 
surface of the NPs.  
In vitro CycA release phenomena from both PBA modified and unmodified PLA-Dex NPs in the 
STF at 35°C were analyzed by quantifying the CycA in the STF at predetermined time intervals using 
HPLC. Both PLA-Dex and PLA-Dex_PBA NPs (PLA-Dex_40PBA and PLA-Dex_320PBA) showed 
total release point at around 120 hrs (Figure 11b), which is significantly longer than some of the 
previous studies involving in vitro release of CycA from micro or nanoparticles [145, 147-149]. 
Moreover, the release rate may potentially be a significant improvement over commercial product 
RESTASIS® which requires administering twice a day. Whereas PLA-Dex NPs showed sustained 
release rate for up to 120 hours, PLA-Dex_PBA NPs showed two regions of slightly different release 
rate. In the first 48hrs, the PLA-Dex_PBA NPs released CycA at a faster rate compared to PLA-Dex 
NPs, which may be due to the release of CycA that were encapsulated near the slightly more 
hydrophobic surface PLA-Dex_PBA NPs. The subsequent slower release rate, compared to PLA-Dex 
NPs, may be due to the release of drugs from the core of the PLA-Dex_PBA NPs, which need to diffuse 
through more compact dextran surface. When the volume of PBA modified NP formulation were scaled 
to the administration volume of RESTASIS® (28 µL), the CycA release rates were in the range of 
µg/day, which is similar to the daily administration dosage of CycA in RESTASIS®. Therefore, it is 
possible to optimize the formulation by changing the concentration of the PBA modified NPs and/or 
the amount of CycA to achieve clinically effective release rate. 
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Figure 11. a) CycA loading and b) In vitro release from PBA modified and unmodified NPs. 
4.4.3 In vitro Mucoadhesion 
Mucoadhesion of the NPs was measured using the in vitro PAS staining method. Compared to the PLA-
Dex and the PLGA-PEG NPs, the PLA-Dex_PBA NPs showed increased mucin adsorption (Table 2). 
PLA-Dex_10PBA, PLA-Dex_40PBA, and PLA-Dex_160PBA NPs showed a slight increase in mucin 
adsorption from 0.575 to 0.605 mg/mg of NPs as the degree of PBA surface functionalization increased. 
However, further increase in PBA surface functionalization (i.e. PLA-Dex_320PBA) decreased the 
amount of mucin adsorbed. It is likely that excess functionalization of the NP surfaces with PBA causes 
the dextran to become more hydrophobic. This would increase the potential for self-aggregation of the 
NPs, reducing the total available surface area for mucin adsorption. It is therefore ideal to tune the 
amount of PBA functionalization to achieve optimal mucin-NP interaction without compromising the 
NP colloidal stability. It is also possible that smaller NPs render higher mucin adsorption due to their 
larger total surface area, as shown by comparing PLGA-PEG, PLA-Dex, and PLA-Dex_PBA NPs. 
However, as each type of NP exhibit different surface properties, the trend is inconclusive. The PLA-
Dex_PBA NPs all exhibited significantly higher mucin adsorption compared to the previous studies 
involving chitosan based NPs and thiolated NPs, which showed about 0.25 and 0.13 mg/mg of NPs 
respectively at 1 hr incubation[146]. Although the current study is limited to in vitro studies, it shows 
great promise for PLA-Dex_PBA NPs as a potential mucoadhesive drug delivery system. 
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4.5 Conclusion 
The surface of the nanoparticle formed from a linear block copolymer poly(D,L-lactide)-b-dextran was 
modified with PBA to form a mucoadhesive nanoparticle for topical ocular drug delivery application. 
The NPs, with sizes around 25 nm and spherical in morphology, encapsulated a therapeutically relevant 
dosage of Cyclosporine A and demonstrated sustained release for up to 5 days. Moreover, in vitro 
mucin-NP interaction was facilitated when the NPs were functionalized with PBA molecules, which is 
difficult to achieve using PEG-based systems. Since PBA functionalization also causes dextran to be 
more hydrophobic, it is ideal to adjust the amount of PBA to achieve optimal mucin-NP interaction 
without compromising the colloidal stability of the NPs. The current report involving various in vitro 
studies provides promising results for the potential use of PLA-Dex_PBA NPs to improve the 
bioavailability of ocular drugs intended to target the anterior segment of the eye. 
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Chapter 5 
Phenylboronic acid modified mucoadhesive nanoparticle drug 
carriers facilitate weekly treatment of experimentally-induced dry 
eye syndrome 
5.1 Summary 
Topical formulations, commonly applied for treatment of anterior eye diseases, require frequent 
administration due to rapid clearance from the ocular surface, typically through the lacrimal drainage 
system or through over-spillage onto the lids. We report on a mucoadhesive nanoparticle drug delivery 
system that may be used to prolong the precorneal residence time of encapsulated drugs. The 
nanoparticles were formed from self-assembly of block copolymers composed of poly(D,L-lactide) and 
dextran. The enhanced mucoadhesion properties were achieved by surface functionalizing the 
nanoparticles with phenylboronic acid. The nanoparticles encapsulated up to 12 wt% of Cyclosporine 
A (CycA) and sustained the release for up to 5 days at a clinically relevant dose, which led us to explore 
the therapeutic efficacy of the formulation with reduced administration frequency. By administering 
CycA-loaded nanoparticles to dry eye-induced mice once a week, inflammatory infiltrates were 
eliminated and the ocular surface completely recovered. The same once a week dosage of the 
nanoparticles also showed no signs of physical irritation or inflammatory responses in acute (1 week) 
and chronic (12 weeks) studies in healthy rabbit eyes. These findings indicate that the nanoparticles 
may significantly reduce the frequency of administration for effective treatment of anterior eye diseases 
without causing ocular irritation. 
5.2 Introduction 
Topical administration of an eye drop solution is the most commonly used drug delivery method for 
treating anterior eye diseases due to its non-invasiveness, low cost and ease of administration. Such a 
delivery method, however, suffers from low ocular bioavailability due to rapid clearance from the 
ocular surface through tear dilution and drainage through the lacrimal drainage system, resulting in less 
than 5% of the active drug reaching its intended target [6]. As a result, high doses of the formulations 
must be administered multiple times per day to achieve therapeutic efficacy, ultimately leading to a 
high risk of adverse effects and low patient compliance. 
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Much effort has been invested in improving topical formulations to overcome these shortcomings 
without compromising their benefits. One such approach includes the development of drug carriers 
developed from polymeric nanoparticles (NPs) [7]. By encapsulating therapeutic agents as their cargo, 
NP drug carriers enhance the solubility of drugs in water, control the release rates of these drugs, and 
improve the precorneal retention by targeting the ocular surface moieties [1, 7, 58, 150]. NPs 
formulated from biodegradable polymers, such as poly(lactic-co-glycolic acid) (PLGA), have been 
studied in the delivery of ocular therapeutics to the corneal surface [9, 33, 67, 68, 151]. Researchers 
have also focused on adding poly(ethylene glycol) (PEG) on the surface of the NPs to improve the 
stability of the NPs in physiological environments as well as precorneal tear fluid [115, 119, 130, 131, 
152-154]. In a previous study, we synthesized a dextran based amphiphilic block copolymer, poly(D,L-
lactide)-b-dextran (PLA-b-Dex), that self-assembles into NPs with sizes ranging from 20 to 60 nm in 
diameter by tuning the molecular weights of PLA and Dex [4]. Dextran based NPs have shown colloidal 
stabilities superior to those of the PEG based NPs previously used [126]. Moreover, dextran has 
abundant functional groups (i.e. OH groups) on its backbone that can be used for modification, as 
opposed to the single functional group on the end of PEG chains. As a result, the high density of surface 
functional groups in dextran based NPs increases the efficiency of surface functionalization and 
consequently provides greater control over surface properties. In previous studies, researchers 
functionalized the surfaces of various NP drug carriers with ligands that can target the ocular mucosa 
to increase the precorneal retention time of the drugs [35, 133-135]. The most common method of 
achieving mucoadhesive properties was through functionalizing the NPs with cationic polymers, such 
as chitosan, to take advantage of the electrostatic interaction between the cationic polymers and the 
negatively charged ocular mucin [52, 91, 110, 147, 155]. However, the electrostatic interaction may be 
partially impeded by the presence of ions in the tear fluid, resulting in the relatively rapid clearance of 
the drug carriers. Phenylboronic acid (PBA) molecules form a complex with cis diol groups of sugar 
residues, such as sialic acids, that are abundant on the mucin structures at physiological pH [137-142]. 
In addition, several studies have demonstrated biocompatibilities of PBA molecules using both in vitro 
and in vivo assays [142, 156, 157]. We hypothesize that the PBA functionalized PLA-b-Dex drug 
carriers will significantly reduce the required dosage of drugs and their administration frequency in 
treating anterior eye diseases by enhancing the precorneal retention of the encapsulated drugs. 
The objective of this study was to develop a mucoadhesive nanoparticle drug delivery system that 
can reduce the administration frequency of ophthalmic drugs without compromising the therapeutic 
efficacy. Here, we report the formulation of PLA-b-Dex polymer nanoparticles with surfaces 
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functionalized with PBA to achieve a mucosal-targeting drug delivery system. We evaluated the ability 
of these nanoparticles to encapsulate Cyclosporine A (CycA), an immunosuppressant commonly 
administered for treating dry eye syndrome, and analyzed the subsequent release profile. We then tested 
the compatibility of these NPs by investigating both the acute and the chronic responses after 
administration on rabbit eyes. Finally, NP+CycA formulations with reduced administration frequencies 
were evaluated for treatment of experimental dry eye induced in mice. 
5.3 Experimental 
5.3.1 Materials 
Acid-terminated poly(D,L-lactide) (PLA; Mw ~20) was purchased from Lakeshore Biomaterials 
(Birmingham, USA) and washed with methanol to remove monomer impurities. Dextran (Dex; Mw 
~10 kDa), hydrochloric acid (HCl), triethylamine (TEA), N-(3-dimethylaminopropyl)-N-ethyl 
carbodiimide (EDC), 3-Aminophenylboronic acid monohydrate (PBA), sodium periodate (NaIO4), 
glycerol, sodium cyanoborohydride (NaCNBH3), and Cyclosporine A (CycA) were purchased from 
Sigma Aldrich (Oakville, Canada) N-Hydroxysulfosuccinimide (Sulfo-NHS) and N-Boc-
ethylenediamine were purchased from CNH Technologies (Massachusetts, USA). 
5.3.2 Synthesis of PLA-b-Dex and surface modification with PBA 
The conjugation of the PLA and Dex polymer chains to form a block copolymer PLA-b-Dex and the 
surface modification of the PLA-b-Dex NPs with PBA were reported in Chapter 3 [4, 158]. Briefly, the 
aldehyde end group of the dextran was conjugated with the N-Boc-ethylenediamine linker through 
reductive amination with NaCNBH3. After conjugation with the linker molecule, the Boc group was 
deprotected using HCl/TEA treatment. The deprotected amine end group is then conjugated with the 
carboxyl terminal group of the PLA using Sulfo-NHS and EDC as catalysts. The surface of these NPs 
were modified with PBA molecules by a two-step approach: the hydroxyl groups of the dextran were 
oxidized to form more reactive aldehyde groups in the presence of NaIO4, and the aldehyde groups 
were conjugated with the amine groups of PBA molecules through reductive amination. The amount 
of PBA attached to the dextran chain was quantified using UV-Vis absorption at 291 nm after obtaining 
the standard calibration of PBA in DMSO. The PLA-b-Dex polymers in DMSO were used as the 
baseline. 
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5.3.3 Characterization of PLA-b-Dex-g-PBA NPs 
The NPs of PLA-b-Dex-g-PBA polymers were formed using nanoprecipitation. The sizes of the NPs 
were determined using dynamic light scattering (DLS) by measuring the multimode-size distribution 
(MSD) volume-averaged mean diameters using a 90Plus Particle Size Analyzer (Brookhaven, λ = 659 
nm at 90°). The zeta potential of the PLA-b-Dex and PLA-b-Dex-g-PBA nanoparticles were measured 
using Zetasizer Nano ZS (Malvern Instruments Worcestershire, U.K.). The sizes and morphology were 
further confirmed using Transmission Electron Microscopy (TEM) equipment by drying the PLA-b-
Dex-g-PBA NP suspension on 300 Mesh Formvar coated copper grids (Canemco and Marivac) and 
using phosphotungstic acid solution as the negative stain. The mucoadhesion of the PLA-b-Dex-g-PBA 
NPs were quantified using an in vitro periodic acid/Schiff (PAS) staining method described previously 
[158]. In brief, the NP suspension and the mucin solution were mixed and incubated at 37 °C for 1 hr. 
The mixture was then centrifuged and the free mucin in the supernatant was quantified using the PAS 
method. Mucin adsorption was calculated by subtracting the free mucin from the initial mucin 
concentration. Mucin standards (0.1, 0.25, 0.5, and 0.75 mg/ml) were also used with the same procedure 
to obtain a calibration curve. 
5.3.4 Animal studies 
All animal studies performed are in compliance with the guidelines of the Canadian Council on Animal 
Care (CCAC) and the University of Waterloo (UW) as well as regulations under the Animals for 
Research Act of Ontario Canada. Female New Zealand White Albino rabbits (2.5 – 3.5 kg, Charles 
River Laboratories, Canada) were used for both the acute and chronic ocular irritancy tests in vivo. 
Female C57BL/6 mice (Charles River Laboratories, Canada) aged around 6-8 months were used for 
experimental dry eye model. All animals were acclimated in the animal facility for at least one week 
prior to the experiments. All formulations used in this study were dialyzed, filtered, and sterilized prior 
to administration to the animals. 
5.3.5 In vivo ocular irritancy test 
The short-term biocompatibility of the NPs was assessed using ocular irritancy tests adapted and 
modified from previous studies [3, 159]. Three female rabbits were housed individually in cages on a 
standard laboratory diet. One eye of each of the rabbits was administered with 28 µl of the PLA-b-Dex-
g-PBA NP formulation (containing about 17 µg of the NPs), while the contra-lateral eye was used as a 
control. Both eyes were observed using a slit lamp bio-microscope at 0 (before administration), 1, 8, 
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24, 48, 72, 96, 120, 144, and 168 hours after administration to examine the extent of irritancy on the 
ocular surface. Upon observation at each time point, both eyes were graded using 7 categories: apparent 
discomfort, conjunctival redness and swelling, lid swelling, discharge, corneal opacification, and 
number of infiltrates from 0 (no sign) to 4 (severe) under the supervision of trained optometrists with 
experience working with animals [90, 160]. After 168 hrs, the rabbits were euthanized and the ocular 
tissues were extracted for histopathology. 
The long-term biocompatibility of the blank NPs and the NPs with Cyclosporine A (NP+CycA) 
encapsulated were assessed using similar techniques described above at 0, 1, 24, and 48hr each week 
repeated for 12 weeks. Five female rabbits were used for blank NP irritancy test and four female rabbits 
were used for NP+CycA irritancy test. Similarly, one eye of each rabbit was administered with 28 µl 
of NP formulation (~17 µg of the PLA-b-Dex-g-PBA NPs) or 28 µl NP+CycA formulation (~17 µg of 
the PLA-b-Dex-g-PBA NPs and <8 µg of CycA (may also include some freely suspended CycA)), 
while the contralateral eye served as a control. Similarly, both eyes were examined under a slit lamp 
bio-microscope on the extent of irritancy based on the 7 categories described above. After 12 weeks, 
the rabbits were euthanized and the ocular tissues were extracted for histopathology. 
5.3.6 Histopathology 
The eyes were enucleated and collected immediately after euthanasia for histopathological evaluation 
by one of the authors (DH), who is a trained pathologist. The entire upper eyelids were also dissected 
and collected for evaluation of the tarsal conjunctiva and the underlying soft tissues. Consecutive 
sections of the entire ocular globe and eyelids were processed for microscopic analysis: after initial 
fixation in 10% neutral buffered formalin, the tissue was embedded in paraffin, serially sectioned into 
5 μm thick sections, and stained with hematoxylin and eosin (H&E). The histological slides were 
evaluated using bright field microscopy (Leica DM1000, ICC50 HD, Leica Microsystems Inc, Canada). 
5.3.7 Experimental dry eye model – in vivo efficacy test 
The PLA-b-Dex-g-PBA NPs encapsulating CycA were analyzed for treating experimental dry eye 
syndrome in a mice model. First, the mice were induced with dry eye conditions using a previously 
reported method [161]. Transdermal scopolamine patches (Transderm-V, Novartis) were cut into two 
pieces each, wrapped around the midtails of the mice, and further secured using surgical tape. The 
patches were replaced every other day throughout the duration of the study. To simulate a desiccating 
environment, the mice cages (open-top) were placed in a fumehood for 1 hr, 3 times per day throughout 
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the study (until day 12). After 4 days of this dry eye inducement procedure, the mice were divided into 
7 different groups (Table 4) for various types of treatments on both eyes (3 mice per group; 6 eyes per 
group) for an additional 7 days. On day 1 (before dry eye inducement), 5 (before first administration), 
8 (before second administration), and 12 (before euthanasia), tear volume measurements and corneal 
fluorescein staining were performed to measure the rate of tear production and analyze the ocular 
surface damage. Note that NP+CycA (1/wk), Saline (1/wk) was only administered on day 5, whereas 
NP+CycA (2/wk), Saline (2/wk), and Blank NPs were administered on days 5 and 8. Tear volume was 
measured by holding a phenol red dyed cotton thread (Zone-quick, White Ophthalmic Supply) with 
jeweler’s forceps in the lateral canthus of the ocular surface for 30 seconds. Corneal fluorescein staining 
was observed and photographed with a slit-lamp bio-microscope using a cobalt blue light 10 minutes 
after the administration of 1 µl of sodium fluorescein solution (10 mg/ml). After the 12 day period, the 
mice were euthanized and the ocular tissues were collected for histopathological analysis (as described 
in the previous section). 
5.4 Results and Discussion 
5.4.1 Characterization of PLA-b-Dex-g-PBA NPs 
We functionalized the surface of PLA-b-Dex NPs, formed from nanoprecipitation, with the mucosal-
targeting ligand PBA (Figure 12). The characterization of the PBA functionalization, the CycA loading, 
and diameters of the NPs are summarized in Table 3. The amount of PBA density on the dextran surface 
was 17.6 ± 2.7 mol% (mol of PBA/mol of dextran monomers). NP diameter decreased from 45.8 nm 
to 28.6 nm likely due to the functionalization with PBA, and was also observed in a similar previous 
study [158]. The size decrease is possibly a result of the reduced hydrophilicity of the dextran surface 
or the change in the packing density of the nanoparticles due to the volume change of the hydrophilic 
chains. We found that having excess PBA (i.e. more than 23 mol% PBA/dextran) on the NP surface 
may cause the NPs to be too hydrophobic and thus compromise its colloidal stability in our previous 
study [158]. Therefore, PBA density must be tuned to balance between mucoadhesion and colloidal 
stability. The NPs exhibited a spherical morphology as observed in TEM imaging (Figure 13). The zeta 
potential of the PLA-b-Dex NPs is close to 0, but when PBA is grafted onto the surface, the potential 
has dropped to near – 30 mV (Table 3). The pKa of the PBA molecules are near 8.6 [162], thus at pH 
~7.4 (at which the measurements were taken) some percentage of the PBA molecules would be in their 
deprotonated state, contributing to the overall negative surface charges of the nanoparticles; similar 
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range of zeta potentials were measured on nanoparticles with PBA molecules on the surface previously 
[163]. The PBA functionalized NPs showed in vitro mucoadhesion properties, resulting in mucin 
binding of 1.18 ± 0.02 mg/mg of NPs, which is much higher than the values obtained for other types of 
mucoadhesive NPs such as chitosan based NPs (~ 0.25 mg/mg of NPs) and thiolated NPs (~ 0.13 mg/mg 
of NPs) [146]. From these preliminary findings we postulate that the PBA functionalized NPs may 
exhibit strong binding affinity toward the ocular mucosa under physiological environment. 
 
Figure 12. Schematic illustration of the self-assembly process to form Cyclosporine A loaded 
PLA-b-Dex-g-PBA nanoparticles, and the mucoadhesion mechanism of the grafted PBA’s. 
 
Table 3. PLA-b-Dex-g-PBA characterization: PBA surface functionalization, Cyclosporine A 
loading, and diameter. 
Sample PBA/Dex  
(mol%) 
CycA load  
(wt%) 
Mean diameter  
(nm) 
ζ potential  
(mV) 
PLA-b-Dex 0 0 45.8 ± 1.5 - 2.63 ± 1.55 
PLA-b-Dex-g-PBA 17.6 ± 2.7 0 28.6 ± 3.1 -31.3 ± 1.5 
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PLA-b-Dex-g-PBA with CycA 17.6 ± 2.7 11.9 ± 1.6 35.6 ± 7.4  
Note that the average and the standard deviations were calculated using measurements of three batches of the nanoparticles  
 
 
Figure 13. TEM image of PLA-b-Dex-g-PBA NPs. 
5.4.2 In vivo ocular irritancy test 
Acute responses after one-time administration of PLA-b-Dex-g-PBA NPs were observed using a slit-
lamp bio-microscope by grading both the NP administered and contralateral control rabbit eyes for 7 
categories over a week (Figure 14). We observed no corneal opacification and infiltrates in any of the 
eyes throughout the study. All of the other 5 categories—discomfort, conjunctival redness and swelling, 
lid swelling, and discharge—also showed no significant difference between the administered and the 
control eyes, similar to what has been observed from chitosan nanoparticles [3]. Most categories 
showed grades between 0 (no sign) and 1 (mild) with the exception of conjunctival redness. As both 
the NP administered and control eyes scored relatively higher grades (between 1 and 2) for conjunctival 
redness, it is highly probably that environmental stress underlies the high scores rather than the 
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administration of NPs. From the slit-lamp examination alone, the NPs seem well-tolerated by the 
rabbits’ eyes, but closer examination of the ocular tissues is necessary to further validate the findings. 
 
Figure 14. In vivo acute ocular irritancy test grading obtained through slit-lamp examination. 
After the slit-lamp examination for a week, the ocular tissues of the rabbits were collected for 
histopathology. Histopathological evaluation revealed the presence of normal ocular surface structures 
in both control and NP administered eyes (Figure 15). All eyes demonstrated preserved architecture 
and morphology in the anterior segment. Corneas of NP administered and control eyes displayed 
normal numbers of cell layers with appropriate morphology (Figure 15, top row). We observed no signs 
of inflammation, altered layer integrity, or the presence of residual particles in any of the eyes. 
Hyperplastic changes, hyperkeratosis, or other alterations in the process of normal epithelial maturation 
and renewal were also not noted. The bulbar and tarsal conjunctiva of both NP administered and control 
eyes revealed findings within normal limits. NP administered and control eyes also showed adequate 
numbers of goblet cells with preserved morphology and abundant secretory products (Figure 15, middle 
and bottom rows). No differences were observed in the size or location of the conjunctiva-associated 
lymphoid tissues. Individual scattered lymphocytes and single polymorphonuclears and eosinophils 
were occasionally observed, predominantly in the tarsal conjunctival epithelium and stroma, in both 
administered and non-administered eyes (Figure 15, bottom row). These findings represent normal 
variations in the tissue characteristics of exposed mucosal membranes expected for healthy subjects. 
There were no inflammation, edema, residual particles, epithelial or vascular abnormalities. The ocular 
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angle demonstrated usual architecture. Both the slit-lamp examination and histopathological 
evaluations suggest that the NP formulation causes no observable acute irritation on the rabbit eyes. 
We expected the appropriate compatibility of NPs, as these NPs were composed of a biodegradable 
polymer chain PLA and a natural polysaccharide dextran, which have both shown in vitro and in vivo 
compatibilities previous studies [4]. In addition, the biocompatible nature of PBA targeting ligands has 
also been demonstrated previously and has since been widely used in in vivo molecular targeting of 
sialic acids expressed on cell surfaces [164]. This study confirms that the combination of the 
biocompatible NPs surface functionalized with biocompatible PBA does not cause any short term 
adverse effects on the ocular surface of the rabbits. 
 
Figure 15. Histopathology analysis of both NP administered and control eyes in in vivo acute 
ocular irritancy test reveal no significant differences in the corneal and conjunctival 
morphological characteristics and architecture. The scale bars (black) are 500 µm in length. 
 
In addition to the acute irritancy study, it is essential to analyze the chronic ocular response to the 
repeated administration of NPs since eye drops are often applied periodically for a prolonged duration 
of treatment. The chronic response on the ocular surface after weekly administration for NPs or 
NP+CycA for up to 12 weeks was also examined using a slit-lamp bio-microscope and the same grading 
system of 7 categories described above. No sign of conjunctival swelling, corneal opacification nor 
infiltrates were observed in any of the eyes throughout the 12 week study. From weekly administration 
of PLA-b-Dex-g-PBA NPs, discomfort, conjunctival redness, discharge and lid swelling levels were 
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mostly in the mild region (between score of 0 and 1), with no significant deviation between the NP 
administered and contralateral control eyes (Figure 16). We also made similar observations after weekly 
administration of CycA encapsulated NPs (NP+CycA): we observed a slow increase of lid swelling 
near the end of the study (week 9 to week 12) to moderate scores of about 1.5 with no apparent deviation 
between the administered and non-administered eyes, suggesting the slow increase was likely due to 
environmental stress (Figure 17). 
 
Figure 16. In vivo chronic ocular irritancy test for weekly administration of NP formulation for 
up to 12 weeks (each data point shown as mean ± s.e.m. (standard errors of mean); n = 5). 
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Figure 17. In vivo chronic ocular irritancy test of weekly administration of NP+CycA 
formulation for up to 12 weeks (each data point shown as mean ± s.e.m.; n = 4). 
Similarly, after the 12 week study, all ocular tissues of the rabbits were collected for histopathological 
analysis. Histopathological evaluation showed all the signs representative of healthy eyes similar to the 
acute irritancy test above (Figure 18). Both NP and NP+CycA treated eyes and their corresponding 
contralateral control eyes demonstrated normal ocular surface structures and anterior eye segments with 
preserved morphology and architecture. All corneas displayed normal numbers of cell layers with 
appropriate morphology without any sign of inflammation, altered layer integrity, or presence of 
residual particles. Hyperplastic changes, hyperkeratosis, or other alterations in the process of normal 
epithelial maturation and renewal were also not noted. Bulbar and tarsal conjunctiva of all eyes revealed 
findings within normal limits: they all showed similar adequate numbers of goblet cells with preserved 
morphology and abundant secretory products. No differences in the size or location of the conjunctiva-
associated lymphoid tissues were observed. Individual scattered lymphocytes and single 
polymorphonuclears and eosinophils were occasionally observed predominantly in the tarsal 
conjunctival epithelium and stroma in all the eyes. No inflammation, edema, epithelial or vascular 
abnormalities were found in either set of rabbits. 
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Figure 18. Histopathology study after in vivo chronic ocular irritancy tests with weekly 
administration of NP and NP+CycA. NP (-) and NP+CycA (-) represent the contralateral 
control eyes of the rabbits administered with NP or NP+CycA formulations. The scale bars 
(black) are 500 µm in length unless otherwise specified. 
The repeated dosage of NPs may increase the potential for adverse effects as their corneal exposure 
time is increased. The study showed that the NPs were well-tolerated for up to 12 weeks, thus 
demonstrating the long-term compatibility of the carrier system. It was also paramount to perform the 
same test on NP formulation with the drugs inside, since the drug encapsulating NPs may exhibit an 
increased diameter due to the increase in the hydrophobic core size, which may or may not lead to a 
varied ocular response. The current study demonstrated that the inclusion of the drug in the NPs did not 
significantly alter the ocular response. These two studies indicate that the NP formulation is a promising 
long term drug delivery system for treating anterior ocular diseases. However, it is not clear how much 
nanoparticles remain after each dosing of the formulation. Therefore, one of the ongoing studies is to 
investigate the dosage-dependency of the ocular compatibility of the nanoparticles by studying their 
ocular biodistribution at predetermined time intervals. 
5.4.3 In vivo efficacy test – experimental dry eye 
Experimental dry eye was induced in mice and 7 different treatments (Table 4) were applied to the mice 
groups to analyze the effect of the treatments against dry eye. Tear volume measurements on day 1 and 
5 (before DE inducement and before 1st admin) suggest that the tear volumes were significantly 
reduced (p < 0.05) (Figure 19) as a result of the combination of application of anticholinergic drug, 
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scopolamine, and the simulation of desiccating environment [161]. The dryness of the eyes were also 
observed in corneal fluorescein staining imaging to varying degrees (Figure 20), between the 1st and 
2nd columns): after 4 days of dry eye inducement, less of the administered fluorescein was cleared 
from the ocular surface compared to day 1 possibly due to the surface damage caused from lack of 
surface lubrication and/or the reduced tear clearance rate. The healthy group maintained a normal tear 
volume production rate with minimal or no ocular surface damage, which resulted in clearance of the 
majority of the fluorescein within 10 mins (Figure 20). Saline (1/wk) and (2/wk) did not show any 
significant improvement in the tear volume production or the fluorescein clearance from day 5 to 12. 
NP+CycA (1/wk) and NP+CycA (2/wk) were the only groups that showed a slight increase in tear 
volume as well as improved fluorescein clearance on day 12 compared to day 5. RESTASIS, 
administered 3 times per day for 7 days, did not show any improvement in tear production on day 12 
compared to day 5. Moreover, the fluorescein images show that less fluorescein was cleared on day 12 
compared to day 5, which is most likely due to the ocular surface damage as a result of frequent 
administration. Blank NPs (2/wk), while showing a certain degree of improvement in terms of 
fluorescein clearance, were unable to clear as much fluorescein as those administered with NP+CycA 
(1/wk) and NP+CycA (2/wk) on day 12. The tear volume measurements suggest that NP+CycA 
formulations showed improved performance in reducing the symptoms of dry eye conditions, however, 
we note that none of the formulations were able to restore the tear volume production of day 1 by the 
end of this study (day 12). We postulate that it may be due to the fact that we are constantly inducing 
dry eye symptoms using anticholinergic agents and therefore it may outweigh the effects of the 
Cyclosporine A treatment. Similar observations were made in a previous study where they showed that 
although the treatment of Cyclosporine A itself showed restored lacrimation but when treated alongside 
anticholinergic agents, the lacrimation was not restored [165]. Thus, closer examination of the 
immunosuppression, which is the main function of Cyclosporine A, is needed to evaluate the efficacy 
of the formulations. 
Table 4. Seven different treatment groups applied to the mice for experimental dry eye 
treatment study in mice. 
Treatment group Dry eye 
induced 
Admin. Admin. 
volume (µl) 
NP  
(µg) 
CycA 
(µg) 
Admin. 
frequency 
Healthy No N/A 0 0 0  
Saline (1/wk) Yes Saline 7 0 0 x1/week 
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Saline (2/wk) Yes Saline 7 0 0 x2/week 
Blank NP (2/wk) Yes Water 7 4 0 x2/week 
NP+CycA (1/wk) Yes Water 7 4 <1.5 x1/week 
NP+CycA (2/wk) Yes Water 7 4 <1.5 x2/week 
RESTASIS Yes N/A 3 0 1.5 x3/day 
 
Figure 19. Tear volume measurements of 7 different treatment groups at 4 time points: before 
dry eye (DE) induction (day 1), before 1st administration (day 5), before 2nd administration 
(day 8), and before histopathology (day 12). Each data point is shown as mean ± s.e.m., n = 6. 
Statistical symbols for t-test: † for 0.05 < p ≤ 0.1, * for 0.01 < p ≤ 0.05, ** for 0.001 < p ≤ 0.01, 
and *** for p < 0.001. 
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Figure 20. Corneal fluorescein staining images of 7 different treatment groups obtain at 4 time 
points: before dry eye (DE) induction (day 1), before 1st administration (day 5), before 2nd 
administration (day 8), and before histopathology (day 12). The images were obtained 10 
minutes after the application of sodium fluorescein. Note that the corneal fluorescein present on 
the edges of the lids were due to the local structure and has little to do with the tear production 
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or ocular surface damage, thus they were not taken into consideration for the fluorescein 
clearance analysis. 
 
Histopathological evaluation of mice in the healthy group showed bulbar and tarsal conjunctiva with 
stratified squamous epithelium, an adequate number of goblet cells with abundant secretory products, 
and complete lack of inflammation (Figure 21, A). The stroma showed occasional single lymphocytes 
and eosinophils within the normal range. The experimental dry eye treated with Saline (1/wk) and 
(2/wk) groups showed pronounced inflammatory changes ranging from focal mild infiltrates to severe 
inflammation (Figure 21, B and C). The inflammatory infiltrates, consisting predominantly of 
lymphocytes with occasional polymorphonuclears and eosinophils, were located in the bulbar and tarsal 
conjunctiva. The infiltrates involved the conjunctival epithelium as well as the subepithelial stroma of 
lamina propria. In addition, substantial areas demonstrated a markedly reduced number or complete 
lack of goblet cells, thereby significantly reducing the mucin secretion and eliminating its lubricating 
and surface protecting effects [166]. Similarly, mice with experimental dry eye treated with Blank NPs 
showed mixed inflammatory infiltrates composed of polymorphonuclears and lymphocytes, with 
occasional plasma cells and eosinophils (Figure 21, D). The bulbar and tarsal conjunctival epithelium 
both showed markedly reduced number of goblet cells. RESTASIS treatment demonstrated clearing of 
the intraepithelial and subepithelial inflammatory infiltrates (Figure 21, G). However, substantial 
residual areas showed complete lack of goblet cells, and goblet cells in isolated areas also exhibited 
altered morphology with scarce secretory products, which explains why the majority of the fluorescein 
was not cleared at the end of the treatment (day 12). Treatment with NP+CycA (1/wk) and (2/wk), like 
RESTASIS, also reversed the inflammatory processes in experimental dry eye induced mice (Figure 
21, E and F). No residual particles, epithelial or vascular abnormalities were found. Individual scattered 
lymphocytes and single polymorphonuclears and eosinophils were observed predominantly in the tarsal 
conjunctival epithelium and stroma at levels similar to those found in Healthy group. The NP+CycA 
treated mice showed adequate number of goblet cells on the ocular surface with normal morphology 
and abundant secretory products. 
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Figure 21. Histopathology analysis of ocular tissues of mice after 7 different treatment types: A) 
Healthy, experimental dry eye treated with B) Saline (1/wk), C) Saline (2/wk), D) Blank NPs, E) 
NP+CycA (1/wk), F) NP+CycA (2/wk), and G) RESTASIS. The scale bars (black) are 300 µm in 
length. The arrows (red) represent some of the inflammatory infiltrates such as lymphocytes, 
polymorphonuclears and eosinophils observed. 
 
Dry eye is characterized as tear deficiency caused by ocular surface inflammation that leads to injury 
to the ocular surface [166]. The histologic features of dry eye include abnormal proliferation of the 
ocular surface epithelium, different degrees of inflammatory changes, and decreased production of 
mucus, manifested by the reduction or absence of goblet cells on the ocular surface epithelium [161]. 
In all three studies, the tear volume measurement, fluorescein clearance, and histopathology, the Saline 
(1/wk) and (2/wk) showed no sign of mitigating the symptoms of dry eye conditions such as lowered 
tear production rate or ocular surface inflammation. This suggests that simple hydration of the ocular 
surface using saline, at the frequency of the administration specified, was not enough to reduce the 
inflammation nor recover the integrity of the ocular surface. Blank NP treatment, similar to saline 
treatment, showed lack of treatment effects of dry eye conditions, but the reduction of goblet cells in 
the Blank NP group was not as drastic as the reduction of goblet cells in the Saline group. We postulate 
that the mucoadhesive NPs, once adhering to the ocular mucosa, may improve the hydration of the 
ocular surface with tear fluid due to the high hydrophilicity of the dextran. This may also explain why 
the NP+CycA groups also resulted in the preservation of the ocular surface, demonstrated by the 
abundance of goblet cells, while RESTASIS treated eyes showed insufficient number of goblet cells 
  58 
and somewhat slower recovery of the ocular surface. Another study reports a significant increase in 
goblet cell density after 3 months of treatment with RESTASIS [167], so it is likely that the recovery 
effect was not observable within the time frame of the current study due to insufficient ocular retention 
of Cyclosporine A from RESTASIS administration. Although the three times daily treatment of 
RESTASIS effectively eliminated the inflammatory infiltrates from the eyes, the NP+CycA treatment 
achieved both the elimination of inflammatory infiltrates as well as the complete recovery of the ocular 
surface with only a single administration per week in the duration of the study. This further implies the 
long retention of these mucoadhesive NPs on the ocular surface, thus immensely enhancing the ocular 
bioavailability and efficacy of the encapsulated drugs. 
Although the current formulation achieved efficacy in treatment of experimental dry eye, there is 
room for further improvement. One of the ongoing studies analyzes the effect of PBA surface density 
on the in vivo retention of the NPs on the ocular mucous membrane, to find the optimal PBA density 
that will maximize its in vivo mucoadhesion without compromising the particle stability. In addition, 
finding the NP:drug ratio that maximizes the total release of the drugs at a therapeutically effective rate 
is also a significant improvement on the current formulation. 
5.5 Conclusion 
Nanoparticles (NPs) self-assembled from PLA-b-Dex copolymers and surface functionalized with PBA 
ligands were formulated as a mucoadhesive drug carrier for topical ocular drug delivery application. 
The NPs encapsulated large dose of Cyclosporine A and sustained the release at a clinically relevant 
dose for a prolonged period of time. Neither the blank NP carriers nor NPs encapsulating Cyclosporine 
A caused any observable irritation or inflammatory responses after weekly administration for up to 12 
weeks observed both by slit-lamp examination and histopathology. The NPs encapsulating 
Cyclosporine A also showed efficacy in treating experimental dry eye in mice: while thrice a day 
administration of RESTASIS only showed clearance of the inflammatory processes, the once a week 
administration of Cyclosporine A loaded NPs demonstrated both the elimination of inflammatory 
infiltrates and the complete restoration of the ocular surface. The current study provides promising 
results for the potential application of PLA-b-Dex-g-PBA NPs to dramatically improve the efficacy of 
ocular therapeutics for treating anterior eye diseases. 
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Chapter 6 
Cyclosporine A loaded mucoadhesive nanoparticle eye-drop 
formulation enhances long term treatment of experimental dry eye 
in mice using a weekly dosing regimen 
6.1 Summary 
Dry eye syndrome (DES) is characterized by a chronic lack of lubrication on the surface of the eye, 
with consequences ranging from mild irritation to extensive ocular surface inflammation. Eye drop 
formulations such as Restasis® (a 0.05% suspension of cyclosporine A, CsA) require frequent dosing 
at high drug concentrations due to rapid clearance from the ocular surface. We developed a 
mucoadhesive nanoparticle eye drop delivery platform to prolong the ocular surface retention of topical 
drugs and studied both its effect on surface retention on the rabbit cornea and its efficacy in treating 
experimentally-induced dry eye in mice by delivering CsA bound to this delivery system. Ocular 
surface retention was studied by measuring the amount of fluorescence after topical delivery of 
nanoparticles encapsulating a near infrared dye, indocyanine green (ICG), to rabbit eyes.  Experimental 
DES was induced in mice by applying scopolamine patches to their midtails and exposing them to 
desiccating environments. These mice were treated with various formulations including 1) Restasis® 
(0.05% CsA, thrice daily), 2) CsA-loaded nanoparticles (NPs) with a CsA dosage 1-2% that of 
Restasis® (NP-CsA 0.005-0.01%, once a week) or 3) NP-CsA 0.025% (once a week) for a month. Dry 
eye status was evaluated by measuring tear production and clearance, and for inflammation and ocular 
surface recovery using histopathology analysis. The ICG encapsulated NPs were clearly visible on the 
ocular surface for up to 24 hrs. Following one month of DES treatment, the once–a–week 
administration of NP-CsA 0.005-0.01% demonstrated elimination of obvious inflammation and total 
ocular surface recovery, whereas the administration of Restasis® or NP-CsA 0.025% only showed 
elimination of inflammatory signs, without recovery of the ocular surface tissues. The mucoadhesive 
nanoparticle eye-drop platform demonstrated prolonged ocular surface retention of ICG in rabbits, and 
effective treatment of dry eye conditions in mice with up to 50 to 100 fold reduction in overall dosage 
of CsA compared to Restasis®, which may significantly reduce side effects and by extending the inter-
dosing interval, improve patient compliance. 
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6.2 Introduction 
Dry eye syndrome (DES) is defined as a multifactorial disease of the tears and ocular surface that results 
in symptoms of discomfort, visual disturbance, and tear film instability with potential damage to the 
ocular surface.[168] DES is also accompanied by increased osmolarity of the tear film and 
inflammation of the ocular surface. Cyclosporine A (CsA, an immunosuppressant agent) 0.05% 
ophthalmic emulsion (Restasis®, Allergen Inc., Irvine, CA) is the first commercially available eye drop 
formulation that showed an increase in natural tear production in dry eye patients, in part by acting to 
reduce both inflammation and concurrent loss of the conjunctival epithelium and goblet cells.[169] Eye 
drops, such as Restasis®, are the most popular method of delivering therapeutics to the eye due to their 
convenience and non-invasiveness, but their biggest challenge is rapid clearance due to tear dilution 
and turnover: more than 95% of the administered drugs are cleared before they reach their intended 
target.[6] Hence, eye drop formulations are often administered frequently (twice daily for Restasis®, 
but up to four times for many topical drugs) at high doses so that the drug concentrations may reach the 
therapeutic window. However, the high overall dosage of the administered drugs results in increased 
side effects: approximately 25% of the people in the phase III safety evaluation of Restasis® reported 
experiencing one or more adverse effects such as burning, stinging and foreign body sensation on the 
ocular surface.[169, 170] Since DES requires constant long-term treatment of its symptoms and signs, 
reducing the dosage of CsA using a more efficient drug delivery platform may likely reduce side effects 
and improve patient compliance, without compromising its therapeutic efficacy. In addition, lower 
administration rates would reduce the likelihood for adverse reactions to the preservatives that are 
commonly included in topical drugs and which are a common cause of ocular surface damage.[171-
174] 
Nanoparticle (NP) as drug carriers have been proposed to address the challenges associated with 
conventional eye drop delivery methods.[1, 7, 14, 32] By encapsulating drugs as their cargo, NPs may 
increase the concentration of drugs in the formulation, control the release rates of the drugs, and 
improve corneal retention by targeting the ocular surface.[58, 150] The controlled release of the drugs 
from the NP drug carriers may also reduce the total amount of drugs exposed on the ocular tissue at 
any given time, thus reducing the risk of side effects. Moreover, the small size of the NP (particle sizes 
≤ 10 µm) eliminates discomfort experienced by users from administration of larger particles.[175] The 
NP formulation may also be tuned to achieve transparency and viscosity similar to that of water. A 
number of polyester based polymers, such as poly(lactic-co-glycolic acid) (PLGA), poly(glycolic acid) 
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(PGA), poly(ε-caprolactone) (PCL), and poly(lactic acid) (PLA) have been explored as suitable 
materials for preparing a NP drug delivery platform for targeting eye diseases.[67, 68, 151, 176-179] 
These NPs have been coated with polyethylene glycol (PEG) to improve their colloidal stability.[115, 
119, 130, 131, 152-154] Recently, we developed an amphiphilic block copolymer composed of 
poly(D,L-lactic acid) and dextran (PLA-b-Dex) to formulate NP drug carriers.[4] Dextran provides a 
unique advantage over PEG-based materials due to its greater hydrophilicity and significantly higher 
density of functional groups for surface modification. Furthermore, dextran based NPs have previously 
demonstrated superior colloidal stability compared to PEG based NPs.[126] Dextran has three hydroxyl 
groups per monomer, whereas PEG only has one functional end group per chain: increased functional 
groups improves the efficiency of surface modification and consequently provides greater control over 
the surface properties of the NPs. Previously, we modified the surface of PLA-b-Dex NPs with 
phenylboronic acid (PBA) molecules to achieve mucoadhesion through covalent linkage between PBA 
and the cis-diol groups of carbohydrates abundant on the ocular mucous membrane.[158] By covalent 
attachment, PBA-modified NPs provide a greater affinity towards mucous membranes compared to the 
more commonly studied mucous-targeting molecules, such as chitosan, which rely on physical 
interaction with the mucous membrane.[52, 91, 110, 147, 155] Since the NPs target the surface mucous 
membrane, the rate of clearance of the NPs is likely reflected by the turnover rate of the ocular mucous 
membrane. We previously demonstrated significantly improved mucoadhesive properties using PBA-
modified NPs, compared to Chitosan-based or thiol-based NPs, and a sustained release of CsA for up 
to 5 days. We further demonstrated that the CsA-loaded NPs were biocompatible on rabbit eyes, and 
effective in treating dry eye conditions in a short term study on mice.[180] We hypothesize that the 
mucoadhesive and controlled release properties of the nanoparticle drug carriers provide a drug delivery 
platform for long term treatment of dry eye using significantly reduced dosage of the drug, while 
maintaining treatment efficacy. The objective of this study is to investigate whether the CsA-loaded 
PBA-modified NPs are able to treat long-term experimental DES using once-a-week dosing (Figure 
22). 
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Figure 22. Preparation of mucoadhesive nanoparticle drug carriers as eye drop formulation. 
 
In this study, experimental DES was induced in mice and nanoparticle formulations with difference 
doses of CsA were applied once a week to treat the dry eye signs. Dry eye treatment efficacy was 
evaluated by measuring for tear production and clearance, and also by evaluating the inflammation and 
ocular surface recovery using histopathology analysis post-euthanasia.  The treatment efficacy of the 
CsA loaded PBA modified NP formulations were compared with Restasis® applied as a topical drop. 
6.3 Experimental 
6.3.1 Materials 
Acid-terminated poly(D,L-lactide) (PLA; Mw ~20) was purchased from Lakeshore Biomaterials 
(Birmingham, USA) and washed with methanol to remove monomer impurities. Dextran (Dex; Mw 
~10 kDa), acetonitrile (ACN), 3-Aminophenylboronic acid monohydrate (PBA), sodium periodate 
(NaIO4), glycerol, sodium cyanoborohydride (NaCNBH3), sodium fluorescein, and Cyclosporine A 
were purchased from Sigma Aldrich (Oakville, Canada). 
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6.3.2 Nanoparticle formulation, and encapsulation and in vitro release of Cyclosporine 
A 
The amphiphilic block copolymer poly(D,L-lactide)-b-dextran (PLA-b-Dex) polymer was prepared in 
Chapter 3.[4] NPs were formed by the self-assembly process of the amphiphilic block copolymer 
through a nanoprecipitation method. To achieve mucoadhesive properties for long retention of ocular 
drugs on the corneal surface, we modified the surface of the NPs with phenylboronic acid (PBA) in two 
steps: the hydroxyl groups of the dextran surface of the NPs were oxidized in the presence of NaIO4, 
and the aldehyde groups were then reacted with the amino groups of PBA using reductive amination in 
the presence of NaCNBH3.[158] 
The encapsulation of raw CsA in the PBA-modified NPs (PLA-b-Dex-g-PBA NPs) was performed 
using a nanoprecipitation method. 1 ml of DMSO containing polymer (~ 7 mg/ml) and CsA (varied 
concentration) was slowly added into 10 ml of Millipore water under gentle stirring for self-assembly 
of NPs carrying the drugs. The NP-drug mixture was then syringe filtered (pore size = 200 nm) to 
remove NP or drug aggregates, and dialyzed against water to remove some of the free drugs and DMSO 
from the mixture. The sizes of the nanoparticles were determined using dynamic light scattering (DLS) 
technique. The amount of CsA in the final mixture was determined using High-performance liquid 
chromatography (HPLC; C18 HPLC column, ACN/H2O 75:25 as the mobile phase, flow rate = 1 
ml/min, UV-absorption detection at 210 nm). 
The encapsulation of CsA in the PBA-modified NPs (PLA-b-Dex-g-PBA NPs) was performed using 
a nanoprecipitation method. 1 ml of DMSO containing polymer (~ 7 mg/ml) and CsA (varied 
concentration) was slowly added into 10 ml of Millipore water under mild stirring for self-assembly of 
NPs carrying the drugs. The NP-drug mixture was then syringe filtered (pore size = 200 nm) to remove 
NP or drug aggregates, and dialyzed against water to remove some of the free drugs and DMSO from 
the mixture. The sizes of the nanoparticles were determined using dynamic light scattering (DLS) 
technique. The amount of CsA in the final mixture was determined using High-performance liquid 
chromatography (HPLC; C18 HPLC column, ACN/H2O 75:25 as the mobile phase with UV-absorption 
detection at 210 nm). 
The CsA in vitro release from the NPs was measured using the method reported previously.[158] 8 
mL of syringe filtered NP-CsA suspension was injected into a Slide-a-Lyzer Dialysis cassette (MWCO 
= 20 kDa, Fisher Scientific) and dialyzed against 300 mL of simulated tear fluid (0.654 g of NaHCO3, 
2.04 g of NaCl, 0.0189 g of CaCl2, 0.414 g of KCl in 300 mL of Millipore water) at 37 °C. 1 mL of the 
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release medium was extracted at each predetermined time points to quantify the amount of CsA using 
HPLC, while 1 mL of fresh simulated tear fluid was added to the release medium 
6.3.3 Animal studies 
All animal studies adhered to the Association for Research in Vision and Ophthalmology (ARVO) 
Statement for the Use of Animals in Ophthalmic and Vision Research. The animal studies were also in 
compliance with the guidelines of the Canadian Council on Animal Care as well as regulations under 
the Animals for Research Act of Ontario Canada. Ethics approval was obtained from the University of 
Waterloo prior to the start of the study. Male New Zealand White (NZW) rabbits (Charles River 
Laboratories, Canada) with average weights of 2.8 to 3.3 kg were used for the ocular surface retention 
study. Female C57BL/6 mice (Charles River Laboratories, Canada) aged 3-5 months were used 
experimental dry eye treatment study. All animals were acclimatized in the animal facility for at least 
one week prior to experimentation. All formulations administered to the mice were sterilized using a 
sterile syringe filters (pore size = 0.2 µm) prior to use. 
6.3.4 Ocular surface retention study on NZW rabbits 
We used ICG as a model drug to estimate change in its retention time as a result of encapsulation and 
delivery with PBA-modified NPs compared against its retention in aqueous solution. NZW male rabbits 
were sedated with acepromazine (2mg/kg) and briefly anesthetized using a mask with 2% isoflurane 
for 10 to 15 minutes for eye drop instillation. After the eye drop instillation, rabbits were transferred 
back to their cages to blink normally. For each rabbit (n = 4), one eye was administered with ICG 
encapsulated NPs (NP-ICG) while the contralateral eye was administered with equivalent concentration 
of ICG in water. We used confocal scanning laser ophthalmoscopy (cSLO; Spectralis®: Heidelberg 
Retinal Angiography 2, Heidelberg Engineering, Germany) for imaging at baseline before 
administration and at 0, 3, 6, 9 and 24 hrs after the initial administration. To image the fluorescence of 
ICG, we used an excitation wavelength of 795 nm and an emission wavelength at 810 nm for all images. 
To achieve standardized images, the power and sensitivity were routinely set at 100% and 90 units, 
respectively, and the relative brightness of the ocular surface images were analyzed using ImageJ.  An 
octagon shape was drawn on the ocular surface to enclose as much area as possible while avoiding the 
bright edges between the corneal surface and the eyelids where dye/particles accumulate due to pooling. 
The average brightness of the area inside the octagon was measured and the background signal was 
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subtracted from it.  All of the means of the fluorescence measurements were normalized with respect 
to the initial mean fluorescence measurements at time 0 hr, right after instillation of the eye drops. 
6.3.5 Dry eye induction and nanoparticle administration on C57BL/6 mice 
To evaluate the efficacy of NPs carrying CsA in treating DES, an experimental murine dry eye model 
was used.[161] Transdermal scopolamine patches (Transderm-V, Novartis; 1.5 mg of scopolamine) 
were cut into two pieces and wrapped around the midtails of the mice and secured with surgical tape. 
The patches were replaced every other day through the duration of the study. To simulate a desiccating 
environment, mice cages (open-top) were placed in a fumehood for 1 hr, 3 times a day throughout the 
study. After 4 days of dry eye induction, the mice were divided into 6 groups of 5 mice and the 
administration of various formulations were initiated (Table 5). Note that dry eye was not induced in 
the Healthy group and no drug was administered to that group of mice. Saline, Blank NP, NP-CsA 
0.005-0.01% and NP-CsA 0.025% were administered once a week (7 µl; on days 5, 12, 19 and 26). 
RESTASIS® was given 3 times a day (3 µ) throughout the study period.[181] On days 5, 12, 19 and 
26, before the weekly administrations, tear production measurement and corneal fluorescein staining 
assessments were performed. On the final day (day 33), the mice were euthanized and the ocular tissues 
harvested for histopathology. 
Table 5. Six different groups applied to the mice for treatment of experimental dry eye 
Treatment group Dry eye 
induced 
Admin. 
volume (µl) 
NP  
(µg) 
CsA 
(µg) 
Admin. 
frequency 
Healthy No 0 0 0  
Saline Yes 7 0 0 x1/week 
Blank NP Yes 7 4 0 x1/week 
NP-CsA 0.005-
0.01% 
Yes 7 4 0.3/0.6* x1/week 
NP-CsA 0.025% Yes 7 4 1.5 x1/week 
Restasis® Yes 3 0 1.5 x3/day 
 
6.3.6 Tear production measurement 
Tear production was measured by holding a phenol red thread (Zone-quick; White Ophthalmic Supply, 
Canada) with jeweler’s forceps in the lateral canthus of the ocular surface for 30 seconds. The length 
of the dyed segment (red) of the thread was measured and recorded. 
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6.3.7 Corneal fluorescein staining 
Corneal fluorescein staining was observed, recorded and photographed with a slit-lamp bio-microscope 
using a cobalt blue light, 10 minutes after the administration of 1 µl of sodium fluorescein solution (10 
mg/ml). 
6.3.8 Histopathology analysis 
The eyes were enucleated and collected immediately after euthanasia for histopathological evaluation. 
The entire upper eyelids were also dissected and collected for evaluation of the tarsal conjunctiva and 
the underlying soft tissues. Consecutive sections of the entire ocular globe and eyelids were processed 
for microscopic analysis: After initial fixation in 10% neutral buffered formalin, the tissue was 
embedded in paraffin, serially sectioned into 5 µm thick sections, and stained with hematoxylin and 
eosin (H&E). The histological slides were evaluated using bright field microscopy (Leica DM1000, 
ICC50 HD, Leica Microsystems Inc, Canada). 
6.4 Results 
6.4.1 Nanoparticle formulation 
The nanoparticles were fabricated with approximately 15.2 ± 1.0 mol/mol% of PBA on dextran 
monomers. The diameter of the raw nanoparticles (Black NPs) was 25.4 ± 0.6 nm (Table 6). With 
encapsulation of CsA, the diameter increased to 29.1 ± 0.3 nm (NP-CsA 0.025%).[158, 180] From the 
HPLC analysis, the NP-CsA 0.025% group contained approximately 1.5 µg of CsA in a 7 µl eye drop 
(along with approximately 4 µg of the PLA-b-Dex-g-PBA NPs) (Table 5). This means that the NP-CsA 
0.025% group had the same amount of CsA in a 7 µl drop as that in a 3 µl drop of Restasis®. Due to 
the dosing frequency differences between Restasis® and NP-CsA 0.025%, the overall dosage of CsA 
in NP-CsA 0.025% is approximately 5% that of Restasis® (or 1/21 that of Restasis®). Similarly, the 
NP-CsA 0.005-0.01% group had 0.3 µg of CsA in the 7 µl drop for the first two weeks of administration, 
and 0.6 µg for the subsequent two weeks. Thus, the dosage of NP-CsA 0.005-0.01% is approximately 
1% that of Restasis® (or 1/105th of Restasis®) for the first two weeks, and 2% (2/105th of Restasis®) 
for the subsequent two weeks. The NP-CsA 0.025% and NP-CsA 0.005-0.01% showed total in vitro 
release for up to 4 and 5 days respectively (Supplementary Figure S1), similar to our previous 
study.[158] 
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Table 6. Nanoparticle diameters and their polydispersity measured using dynamic light 
scattering (DLS). 
 MSD* diameter (nm) Polydispersity 
Blank NPs 25.4 ± 0.6 0.240 ± 0.005 
NP-CsA 0.005-0.01% 26.9 ± 1.1 0.317 ± 0.001 
NP-CsA 0.025% 29.1 ± 0.3 0.199 ± 0.002 
 
6.4.2 Ocular surface retention study 
To analyze the effect of mucoadhesive NPs on ocular surface retention, ICG was used as a model drug 
for imaging the corneal surface of rabbit eyes using cSLO. Standardized images SLO (Figure 23) 
showed that the ICG delivered using NPs (NP-ICGs) demonstrated higher retention of ICG compared 
to the ICG control, which was especially noticeable at the 6 hr time-point (Figure 23): up to 17.5% of 
the initial ICG from NP-ICGs administration was still retained after 6 hrs whereas only about 2.81% of 
the ICG was retained after administration of free ICG solution (Figure 24). At 30 hr, both the ICG and 
the NP-ICG showed baseline level of fluorescence. 
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Figure 23. Fluorescence images of NZW rabbit eyes treated with ICG and ICG-NP taken using 
confocal Scanning Laser Ophthalmoscopy (cSLO). 
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Figure 24. ImageJ analysis of the fluorescence images taken from rabbit eyes treated with ICG 
and NP-ICG (n = 4; mean ± s.e.m.). I: mean fluorescence intensity measured using ImageJ 
software; I0: initial fluorescence (at 0 hr). 
6.4.3 Tear production and corneal fluorescein clearance on C57BL/6 mice 
To evaluate the efficacy of the CsA loaded NPs in treating DES, tear production measurements and 
corneal fluorescein staining analysis were performed each week right before the dosing of the various 
formulations on mice. All the groups (with the exception of the Healthy control group) underwent dry 
eye induction, which was reflected in the sudden drop of tear production after 4 days (i.e., on day 5) 
(Figure 25). The Healthy group maintained a relatively stable tear production throughout the study 
except on week 3 (day 26). Interestingly, this slight drop in tear production is also reflected on the 
reduced corneal fluorescein clearance (Figure 26, top row) observed on day 26, while on all the other 
measurement time points the fluorescein was rapidly cleared from the corneal surface within 10 
minutes. The tear production for all the treatment groups remained at or below half of the initial tear 
production rate throughout the duration of the study. Only the NP-CsA 0.025% group was able to 
significantly increase its tear production at the end of the study (day 33) compared to before the start 
of weekly administrations (day 5) (p < 0.05), but it was only able to restore up to about 50% of the 
initial tear production rate (day 1). These findings were also corroborated by the corneal fluorescein 
staining analysis. All groups (excluding the Healthy control group) showed a similar dryness on the 
eye: compared to the Healthy group, all groups showed a relatively high amount of fluorescein staining 
on the corneal surface due to the ocular surface damage inflicted by the dryness induced by the 
treatment. Only the NP-CsA 0.005-0.01% group showed an improvement by the end of the study 
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compared to its earlier measurements in terms of corneal fluorescein staining, whereas the NP-CsA 
0.025% group showed improvements up to week 2 (day 19), but showed a worsening effect from day 
19 until day 33. 
 
Figure 25. Tear production measurement of mice with different treatment groups. The tear 
volumes (T) were normalized with respect to their initial tear volume (T0). The arrows 
represent the weekly dosing regimen of Saline, Blank NPs, NP-CsA 0.005-0.01% and NP-CsA 
0.025% groups. 
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Figure 26. Corneal fluorescein staining analysis of mice with different treatment groups. The 
arrows represent the weekly dosing regimen of Saline, Blank NPs, NP-CsA 0.005-0.01% and 
NP-CsA 0.025% groups. Note that the analysis does not take into account the fluorescein on the 
lid margins of the eyes. 
6.4.4 Histopathology analysis 
The ocular tissues of the mice in the Healthy group showed all the signs of healthy eyes. The 
conjunctival epithelium displayed surface epithelium cells with normal morphology and architecture 
along with abundant goblet cells which indicated the presence of adequate conditions for production 
and formation of a stable tear film layer on the surface of the ocular mucous membrane (Figure 27, A). 
The lamina propria were composed of loose connective tissues with occasional lymphocytes, and 
showed no evidence of acute or chronic inflammation. By contrast, in the DES groups treated with both 
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the Saline and Blank NPs showed conjunctival epithelium and lamina propria changes consistent with 
disease (Figure 27, B and C). There were mild to moderate levels of mixed inflammatory infiltrates 
composed of lymphocytes and occasional polymorphonuclears leucocytes, indicated by the red arrows 
in the figure. The epithelium was thinned out and showed marked reduction, or in some cases, complete 
absence of goblet cells. The mice treated with NP-CsA 0.005-0.01% showed conjunctiva with no signs 
of inflammatory infiltrates (Figure 27, D), displaying morphological features similar to those seen in 
the Healthy mice group. Moreover, the surface epithelium demonstrated partial to complete recovery 
of the goblet cells. In terms of the number of goblet cells, the majority of the surface epithelium of the 
eye samples in this group closely resembled the Healthy group. Similarly, the mice treated with higher 
dose of CsA loaded NPs (NP-CsA 0.025%) showed no signs of inflammatory infiltrates (Figure 27, E). 
However, the ocular specimens in this group demonstrated a significantly reduced amount of goblet 
cells on the surface, and in some cases, complete lack of goblet cells. The mice treated with the 
commercial form of CsA, RESTASIS®, similarly showed no signs of inflammation, but similar to the 
NP-CsA 0.025% group, the surface epithelium remained thinned and was completely deprived of goblet 
cells (Figure 27, F). 
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Figure 27. Histopathology analysis of ocular tissues of mice with different treatments: A) 
Healthy, B) Saline, C) Blank NPs, D) NP-CsA 0.005-0.01%, E) NP-CsA 0.025%, and F) 
Restasis®. The scale bars are 100 µm in length. The red arrows represent some of the 
inflammatory infiltrates such as lymphocytes, polymorphonuclears and eosinophils observed. 
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6.5 Discussion 
Mucoadhesive NPs were developed to enhance the delivery of ocular therapeutics to the anterior 
segment of the eye. PLA-b-Dex NPs, with PBA grafted onto the dextran surface for mucosal targeting, 
previously showed enhanced in vitro mucoadhesion and sustained release of CsA from the NPs for up 
to 5 days.[158] In a subsequent study, we demonstrated that the CsA loaded NPs showed compatibility 
on rabbit eyes and efficacy in treating experimental DES in mice using once a week administration.38 
Because the previous studies were limited to a short term treatment period of 1 week, the aim of the 
current study was to evaluate long term treatment effects administering CsA loaded NPs once a week. 
The experimental DES was induced in mice using the combination of transdermal application of 
anticholinergic agents, scopolamine, and the exposure to desiccating environments, as reported in 
previous studies.[161, 182] From these studies, we hypothesized that the mucoadhesive and sustained 
release properties of the NPs prolong the retention of CsA, thus allowing for the treatment of dry eye 
with significantly reduced dosage of CsA in the formulation. 
In this study, we visually demonstrated the prolonged retention of the model drug, ICG, when 
delivered with PBA modified NPs in vivo compared against an aqueous solution ICG encapsulated in 
NPs showed increased retention on the surface of rabbit eyes for up to 24 hrs (Figure 23 & Figure 24). 
At 30 hr, signals from both the NP-ICG and the aqueous ICG formulations decreased to the baseline 
levels, implying that the ICG was cleared and/or photobleached (Figure 24). Considering the rapid 
clearance of Restasis® from the ocular surface within the first 20 minutes of eye drop 
administration,[183] these data demonstrate that PBA modified NPs significantly prolong the ocular 
retention of loaded therapeutics by attaching to the ocular mucous membrane. Previous studies 
demonstrated improved retention of CsA by encapsulating them in non-PBA NPs but the CsA 
concentration in the lachrymal fluid quickly reached baseline levels after the first few hours.[184, 185] 
This study further corroborates previous in vitro data showing imaging mucoadhesive properties of the 
PBA modified NPs due to covalent linkage to mucin.[158] 
We next studied how prolonged ocular retention of drugs could improve the long term treatment 
effect of CsA-loaded NPs on dry eye conditions induced in mice. The dry eye induction was confirmed 
by the drastic drop in tear production rate within 4 days (Figure 25), as well as the increased amount of 
fluorescein staining on the corneal surface (day 5) compared to the Healthy control group (Figure 26). 
From both tear production measurements and fluorescein staining analysis, most of the mice in the 
groups after dry eye induction (excluding the Healthy group) maintained the dry eye conditions 
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throughout the study (from day 5 to day 33) without much improvement in these clinical parameters. 
The only groups that showed statistically significant improvements between day 5 and day 33 were the 
Saline and NP-CsA 0.025% groups (p < 0.05), but comparably, the increased tear production is only at 
50% of the initial tear production rate. This phenomenon was also observed in our previous short term 
treatment study.[180] Since the dry eye induction procedures (scopolamine and desiccating 
environment) were maintained throughout the study, their effects were likely too overwhelming for the 
treatment effects of CsA. Although the tear production improved for NP-CsA 0.025%, the corneal 
fluorescein staining only improved up to day 19 and gradually worsened toward the end of the study, 
implying distinct ocular surface damage. To better understand the treatment effects of the 
immunosuppressant agent, CsA, closer examination of the ocular surface was conducted using 
histopathology, to identify signs of inflammation and ocular surface integrity. The ocular tissues of the 
Saline and Blank NPs group showed that these formulations were unable to treat the symptoms of DES, 
demonstrating pronounced inflammation and a complete lack of goblet cells on the ocular surface 
(Figure 27). It is possible that Blank NPs group may further induce inflammation due to the degradation 
of the PLA chains. However, in our previous study, we showed that the NPs themselves did not cause 
any inflammation after weekly dosing of up to 12 weeks.[180] It is likely that the timeframe for NP 
clearance with the mucous membrane is shorter than that of hydrolytic degradation of the PLA 
polymers.[186, 187] All three formulations containing CsA (NP-CsA 0.005-0.01%, NP-CsA 0.025%, 
and Restasis®) showed elimination of inflammatory infiltrates, which is the main function of CsA. 
However, only the NP-CsA 0.005-0.01% group showed recovery of the ocular surface in addition to 
the lack of inflammatory infiltrates. In our previous study, we observed the elimination of inflammation 
and full recovery of the ocular surface with NP-CsA 0.025% group for the 1 week treatment study.[180] 
In this study, after 4 weeks of treatment, the NP-CsA 0.005-0.01% showed both the elimination of 
inflammation and the recovery of the ocular surface while NP-CsA 0.025% only showed elimination 
of inflammation without the full ocular surface recovery. We speculate that NP-CsA 0.025% group 
likely had sufficient CsA to treat DES in 1 week, but when this dosage was repeated for 4 weeks, the 
prolonged exposure to this dose may have slowed down or prevented the recovery of the ocular surface. 
The long term toxicity of CsA on the ocular surface has not been well documented in the past,[188] 
likely due to rapid ocular clearance of CsA using conventional formulations. We hope to further 
investigate the long term effect of CsA on ocular surface as a result of mucoadhesion of the drug 
carriers, especially in terms of recovering the ocular surface tissues. The mice treated with Restasis® 
also showed similar effects, likely due to the frequent exposure (thrice daily) to the high concentration 
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CsA in the precorneal tear fluid. Therefore, we believe that it is necessary to lower the dosage of the 
CsA in the mucoadhesive NPs even further, from 5% of Restasis® (NP-CsA 0.025%) to 1 to 2% (NP-
CsA 0.005-0.01%), for long term treatment of DES to facilitate the ocular surface recovery without 
compromising the therapeutic efficacy. 
6.6 Conclusion 
PLA-b-Dex NPs surface grafted with PBA ligands were formulated as a mucoadhesive NP eye drop 
delivery platform. The mucoadhesive nature of the NPs were further demonstrated by showing 
enhanced ocular retention of the fluorescent dye, ICG, delivered using the NPs compared to ICG 
delivered without the NPs. Both once a week administration of NPs (NP-CsA 0.025%) and three times 
daily administration of Restasis® to dry eye induced mice showed elimination of inflammatory 
infiltrates but failed to fully recover the ocular surface. However, once a week dosing of NPs with an 
even lower dosage (NP-CsA 0.005-0.01%) showed efficacy in terms of both the elimination of 
inflammatory infiltrates and the full recovery of the ocular surface, as determined by histopathology. 
The current study provides promising results for the potential application of PBA-grafted mucoadhesive 
NPs to dramatically prolong the dosing interval, increase compliance and improve the efficacy of CsA 
and other ocular therapeutics for treating anterior eye diseases. 
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Chapter 7 
A novel method for chemically modifying carbohydrates using a 
semi-solid state reaction 
7.1 Summary 
Carbohydrates are abundantly used in drug delivery applications – often as the shell material in 
designing drug delivery vehicles. However, chemically modifying the carbohydrates to achieve desired 
surface functionality for the drug delivery vehicles requires long reaction time and numerous steps. 
Here we propose a novel semi-solid state reaction to chemically modify carbohydrates. The method 
avoids degradation or caramelization of the carbohydrates by avoiding the use of high temperatures, 
which is normally associated with solid-state chemistry, by incorporating a small amount of water to 
act as a “plasticizer”. We used dextran as our model carbohydrate and conjugated 4-
(bromomethyl)phenylboronic acid (BPBA) onto dextran using this new approach. NMR analysis 
demonstrated that the conjugation reaction may have reached saturation level by as early as 10 minutes 
at temperatures from 70 to 110 °C. By tuning the reaction temperature and the ratio of the reactants, we 
achieved conjugation efficiency of 42.4 mol/mol% for BPBA/dextran(monomer), which is unattainable 
using same conditions in a solvent reaction. We believe that this novel semi-solid state reaction will 
significantly improve the utility of carbohydrates for diverse applications in the field of biomedical 
engineering. 
7.2 Introduction 
Carbohydrates are extensively used in drug delivery and tissue engineering applications due to their 
biocompatible nature [189, 190]. Recently, numerous researchers used carbohydrates as the shell 
material for nanoparticle (NP) drug delivery systems for their hydrophilic nature and also because of 
the numerous functional groups on their backbone [120]. These functional groups on the NP drug 
carriers can be chemically modified with a molecule to achieve specific surface functionality such as 
targeted therapy. However, surface modification of NPs frequently requires multiple steps, long 
reaction times, and/or organic solvents that may not be regarded as safe. 
Recently, solid state chemistry has gained much attraction as an alternative method to the 
conventional solvent chemistry due to their rapid reaction rates [191]. A typical solid state reaction 
requires melting of the reactants together for the reaction to proceed, without the need for a liquid 
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reaction medium. This is also advantageous for biomedical application since there is no organic solvent, 
that may be unsafe, to be purified from the final products. Nevertheless, it is difficult to carry out 
conventional solid state reactions for carbohydrates since the high temperatures required for the 
reaction may lead to caramelization and/or degradation of the carbohydrates. 
Here we propose a slight variation of the solid state reaction to address this issue. By adding a small 
amount of water to the carbohydrate reaction mixture, we believe that we can significantly lower the 
temperature for effective reaction, thus maintaining the integrity of the carbohydrates for the reaction. 
Since carbohydrates are soluble in water, water may act as a “plasticizer” in this reaction to lower the 
reaction temperature without affecting the reactivity of the process. The addition of water causes the 
solid reactants to become a paste-like material, which then phase-transitions into a viscous gel-like 
mixture at an elevated temperature to facilitate the reaction. We hypothesize that this new semi-solid 
reaction can be utilized to chemically modify carbohydrates with rapidity and simplicity. 
To demonstrate the semi-solid state reaction, we used dextran as our model carbohydrate in this 
study, and we modified it with a 4-(bromomethyl)-phenylboronic acid using Williamson ether synthesis 
mechanism. Dextran, a polysaccharide made of glucose units, is one of the many carbohydrate materials 
extensively used in various biomedical applications [192-194]. Straight chains of dextran consists of α-
1,6 glycosidic linkages, while the branched dextran forms α-1,3 linkages. Previously, we surface 
modified dextran based NPs with phenylboronic acid molecules to develop a mucosal targeting NP 
drug delivery platform [158, 180]. 
7.3 Experimental 
7.3.1 Materials 
Acid-terminated poly(D,L-lactide) (PLA; Mw ~ 20 kDa) was purchased from Lakeshore Biomaterials 
(Birmingham, USA) and washed with methanol to remove monomer impurities. dextran (Dex; Mw ~ 
10 kDa, mostly linear), sodium tert-butoxide (tBuONa), 4-(bromomethyl)phenylboronic acid (BPBA), 
hydrochloric acid (HCl), triethylamine (TEA), N-(3-dimethylaminopropyl)-N-ethylcarbodiimide 
(EDC), and sodium cyanoborohydride (NaCNBH3) were purchased from Sigma Aldrich (Oakville, 
Canada). N-Hydroxysulfosuccinimide (Sulfo-NHS) and N-Boc-ethylenediamine were purchased from 
CNH Technologies (Massachusetts, USA). 
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7.3.2 A semi-solid state chemistry to chemically modify dextran with 4-
(bromomethyl)phenylboronic acid 
The Williamson ether synthesis between dextran and BPBA were performed in semi-solid state by 
adding a small amount of water to the mixture. We used dextran as the model carbohydrate and BPBA 
as the small molecule with bromo functional group, and to catalyze the Williamson ether conjugation 
between BPBA and dextran, we used tBuONa as the strong base (Figure 28). To perform the 
conjugation, we added all three ingredients, dextran, tBuONa, and BPBA, in a mortar and used a pestle 
to mix the powders as thoroughly as possible. During mixing, water drops (125 wt% of dextran) were 
added to create a paste-like mixture. The mixture was then transferred to a scintillation vial with a 
sealed cap and placed inside a pre-heated oven. The samples after reaction were washed with methanol 
multiple times to remove tBuONa and unreacted BPBAs. The samples were dried overnight in a 
vacuum desiccator before characterization with 1H NMR. The conjugation efficiency of BPBA on 
dextran was calculated by integrating the peaks in NMR spectra after baseline adjustment: the peaks 
that correspond to the protons in the phenyl group of the BPBA (near 7.4 ppm and 7.8 ppm) were 
normalized against the peak corresponding the protons on dextran carbon 1 in the monomer (near 5.2 
ppm). 
 
Figure 28. Reaction scheme for the Williamson ether synthesis between dextran and 4-
bromomethylphenylboronic acid (BPBA), using sodium tert-butoxide (tBuONa) as the catalyst. 
Note that the BPBA is shown to have reacted with the hydroxyl group on C2 of the dextran 
repeating unit, but BPBA may also attach to the hydroxyl groups on C3 and C4. 
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7.4 Application of the semi-solid state chemistry in synthesizing BPBA modified 
dextran based nanoparticles 
The semi-solid Williamson ether conjugation method described above was applied in synthesizing a 
block copolymer between poly(D,L-lactide) and BPBA modified dextran. The current semi-solid state 
conjugation method was incorporated into the previous procedure for synthesizing PLA-Dex block 
copolymer [4, 158]. Briefly, the dextran end group was conjugated with N-Boc-ethylenediamine 
through reductive amination. The semi-solid state conjugation method was incorporated in the next step 
to conjugate BPBA to the hydroxyl groups of dextran backbone using 
dextran(monomer):tBuONa:BPBA molar ratio of 1:2:1 with reaction temperature of 110 °C for 10 
mins. Subsequently the amine group protected by the Boc group was deprotected through HCl and TEA 
treatments. Finally, the amine group of the PBA-dextran end group was conjugated with the carboxyl 
group of PLA terminal group using EDC and Sulfo-NHS as catalysts. The intermediate and the final 
product from all 4 steps were analyzed and verified using 1H NMR. 
7.5 Results and discussion 
7.5.1 Conjugation of BPBA onto dextran using semi-solid state chemistry 
We performed semi-solid state reaction to chemically modify the dextran with BPBA using Williamson 
ether synthesis mechanism and we evaluated the BPBA/dextran conjugation efficiency using 1H NMR 
after removing unreacted BPBAs from the mixture. The 1H NMR spectrum obtained from the procedure 
of this reaction showed the presence of peaks near 7.4 ppm which corresponds to the protons at C2 and 
C6 of BPBA, and 7.8 ppm which corresponds to the protons on C3 and C5 (Figure 29). 
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Figure 29. 1H NMR analysis of the semi-solid state chemistry on BPBA modified dextran in D2O 
after purification of unreacted BPBA and tBuONa. 
7.5.2 Effect of the reaction time and the temperature 
Semi-solid state reactant mixtures were placed in an oven with varying temperatures and reaction times 
to determine their effects on the conjugation efficiency between BPBA and dextran. The conjugation 
of BPBA on dextran increased with increasing reaction temperature but it was unaffected by the 
reaction time (Figure 30): there was no significant difference among the conjugation efficiencies from 
10 min to 2 hrs of reaction time for each reaction temperature of 70, 90 or 110 °C (student t-test: p < 
0.05). This result is in agreement with the fast nature of solid-state reactions [191]. Increasing the 
reaction temperature increased the BPBA-Dextran conjugation efficiency, which suggests that higher 
temperature directly translates to higher reaction kinetics of the Williamson ether mechanism. We 
observed that the all the reaction mixtures coming out of the oven exhibited a gel-like viscous nature, 
which implies that the initial paste-like mixtures went through a phase-transition into a supersaturated 
liquid mixture at the elevated reaction temperatures. Thus, we avoided increasing the reaction 
temperature near the melting point of at least one of the reactants, which in this case is at least 170 °C, 
by adding a small amount of water. At 130 °C, the samples turned brown after 10 mins and 30 mins 
which implies the caramelization of the dextran [195] and no further reaction durations were examined. 
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Figure 30. Effect of reaction time and temperature on the BPBA:dextran conjugation efficiency. 
7.5.3 Effect of the ratio of the reactants 
We investigated the effect of the molar ratios BPBA:dextran (note that mole of dextran throughout this 
study represents the mole of the dextran repeating units) and tBuONa:dextran on the conjugation 
efficiency between BPBA and dextran using the semi-solid state method. While keeping the 
tBuONa:dextran molar ratio constant (1:1) and using the optimal reaction conditions of 10 mins at 110 
°C, we varied the ratio of BPBA:dextran to study its effect on the BPBA/dextran conjugation efficiency. 
Conjugation efficiency decreased with the increasing amount of BPBA with respect to dextran in the 
mixture (Figure 31). It is likely due to the side reactions that BPBA undergo among themselves to form 
trimeric anhydrides, boroxines, especially under dehydrating conditions [196]. The excess BPBA’s in 
the mixture may promote the formation of these boroxine complexes rather than forming ether linkages 
with deprotonated hydroxyl groups of dextran. We believe that the use of an alternative targeting ligand 
which do not undergo side reactions among themselves may still increase the conjugation efficiency 
linearly with increasing molar ratio of the targeting ligand to dextran monomers. On the other hand, the 
conjugation efficiency of BPBA on dextran increased with increasing ratio of tBuONa:dextran while 
keeping the BPBA:dextran molar ratio constant at 1:1 (Figure 32). With tBuONa:dextran ratio of 4:1, 
the BPBA/dextran conjugation reached 42.4 mol/mol %. The result implied that the more tBuONa 
added, the more hydroxyl groups were deprotonated, leading to higher number of ether linkages formed 
with BPBA’s present in the mixture. When we performed the Williamson ether synthesis using the 
same reaction temperature and the same duration in a solvent condition (using water as the solvent), 
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the conjugation efficiency was in the range of 1 to 3 mol/mol%. These result provide us with a great 
flexibility in tuning the desired conjugation efficiency using this semi-solid state reaction chemistry. 
 
Figure 31. Effect of the molar ratio of BPBA to dextran repeating unit on the BPBA:dextran 
conjugation efficiency. The molar ratio of tBuONa to dextran repeating unit is kept constant at 
1. 
 
Figure 32. Effect of the molar ratio of tBuONa to dextran repeating unit on the BPBA:dextran 
conjugation efficiency. The molar ratio of BPBA to dextran repeating unit is kept constant at 1. 
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7.5.4 Application of the semi-solid state chemistry in synthesizing BPBA modified 
dextran based nanoparticles 
After obtaining the results on the effect of various parameters on the conjugation efficiency of BPBA 
on dextran, we employed this method into synthesizing a poly(D,L-lactide)-b-dextran (PLA-Dex) block 
copolymer with BPBA groups grafted onto the dextran. Previously, we developed a method for 
synthesizing a PLA-Dex block copolymer [4], and subsequently modifying the dextran surfaces with 
phenylboronic acid derivatives after forming the nanoparticles using the PLA-Dex block copolymers 
[158]. The previous method required multiple reaction and purification steps as well as long reaction 
times to graft 3-amino-phenylboronic acid onto periodate oxidized dextran monomers. The current 
semi-solid state method uses a single step approach to graft BPBA onto the hydroxyl groups of dextran 
without the need for pre-treatment of the dextran molecules (i.e. periodate oxidation). The simplicity 
of the reaction combined with the short reaction time (i.e. 10 mins at 110 °C) of the semi-solid state 
chemistry provides a significant improvement in the synthesis of PLA-Dex-g-PBA block copolymers. 
Using the optimal reaction conditions of 110 °C for 10 mins and 1:2:1 as the molar ratio for dextran-
NH-Boc:tBuONa:BPBA, we synthesized the dextran-NH-Boc (prepared from step 1 in Figure 33) with 
about 17.6 mol/mol% of BPBA grafted onto the dextran backbone in step 2 of the proposed reaction 
scheme (Figure 33), which was within the range of values obtained using the previous method with a 
much longer reaction time and many more steps [158]. The four steps of the reaction to synthesize 
PLA-Dex-g-PBA involving the semi-solid state chemistry were verified using NMR (Figure 34). The 
semi-solid state method provides an alternative approach in chemically modifying carbohydrates that 
is fast, simple, and tunable. We demonstrated that this new method can be incorporated into existing 
block copolymer synthesis methods to significantly speed up and simplify the fabrication process 
without compromising the conjugation efficiency of grafting the ligands onto the backbone of 
carbohydrates. 
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Figure 33. Reaction scheme: application of the semi-solid state method in synthesizing a block 
copolymer between BPBA modified dextran and poly(D,L-lactide) (PLA). 
 
Figure 34. 1H NMR analysis of the all 4 steps on the PLA-Dex block copolymer synthesis with 
BPBA grafted dextran. Note that D2O was used for analysis on the products of steps 1 to 3, and 
DMSO-d6 was used for the analysis of product on step 4. 
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7.6 Conclusion 
Due to the rapid advances in the use of carbohydrates in a wide range of biomedical applications, there 
is a need for simple and rapid method to chemically modify the carbohydrates to achieve various 
functionalities. We developed a semi-solid state reaction method to chemically modify carbohydrates 
in a simple and rapid manner. The method benefits from the rapid reaction rates associated with 
conventional solid-state chemistry while avoiding the need of high reaction temperatures by adding a 
small amount of water to act as “plasticizer”. By using dextran as a model carbohydrate, we 
demonstrated conjugation of BPBA onto dextran within 10 minutes of the reaction at temperatures 
between 70 to 110 °C. By tuning the reaction temperature and the ratios of the reactants, we showed 
that the semi-solid state method provides a wide range of tunability to achieve desired conjugation 
densities on dextran. To demonstrate the applicability of this new method, we incorporated the semi-
solid state reaction into our existing block copolymer synthesis between PLA and BPBA modified 
dextran. The new method achieved similar properties using much shorter reaction duration with 
significantly reduced number of steps. We believe that this novel semi-solid state chemistry can be used 
for many different carbohydrates to significantly broaden their scope of application in the field of 
biomedical engineering. 
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Chapter 8 
Conclusions and Future Work 
8.1 Summary 
This thesis presents the development of a nanoparticle (NP) drug delivery system to enhance the ocular 
surface retention of therapeutics delivered to the anterior segment of the eye. The NPs were comprised 
of amphiphilic block copolymers formed between dextran and poly(D,L-lactide). The surfaces of the 
NPs were chemically modified with phenylboronic acid, which can covalently bind to diol groups that 
are commonly found in ocular mucous membranes, for mucoadhesive targeting. The NPs showed 
mucoadhesive properties and were able to release the therapeutically relevant dosage of Cyclosporine 
A (CsA), a drug commonly used to treat dry eye syndrome, for up to 5 days in vitro. The weekly 
administration of NPs containing CsA showed biocompatibility and efficacy in treating experimental 
dry eye in animal models. The dosage of CsA in the NP formulation was optimized to 50- to 100-fold 
less than the commercial product, Restasis®, in the long term treatment of experimental dry eye in 
mice, successfully eliminating inflammation as well as recovering the ocular surface goblet cells. 
Thrice daily treatments using Restasis® in the same experiment were only able to eliminate the 
inflammation without recovering the ocular surface integrity. The mucoadhesive property of the NPs 
was further demonstrated in animal models by showing prolonged ocular retention of a fluorescent dye 
delivered topically to the eyes using the same NPs. Finally, to demonstrate the feasibility of the NP 
formulation to advance to clinical trials, we developed a semi-solid state reaction process to synthesize 
the building block of the NPs – the block copolymer with phenylboronic acid grafted on the dextran – 
in a simple, fast, and scalable manner. 
8.2 Conclusions 
NP drug carriers were formed by a self-assembly process of an amphiphilic block copolymer in a 
controlled environment. For this thesis, we synthesized an amphiphilic block copolymer by covalently 
linking two polymers: poly(D,L-lactide) (PLA), a biodegradable biomaterial, and dextran, a natural 
polysaccharide that has an abundance of functional groups for surface modification of the NPs to 
achieve desired surface properties. The sizes of the NPs were in the sub-100 nm range and were 
tuneable based on the molecular weight of the PLA and/or dextran used to form the block copolymer.  
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The surfaces of the self-assembled polymeric NPs were chemically modified using phenylboronic 
acid (PBA) for mucous membrane targeted delivery of nanoparticle drug carriers. The amount of PBA 
per dextran monomer was tuneable by changing the initial reaction conditions. The PBA-modified 
nanoparticles demonstrated two to five times improvement in mucoadhesion compared with other types 
of mucoadhesive particles reported in the literature, such as chitosan or thiol-modified particles, in an 
in vitro study. The PBA-modified NPs encapsulated clinically relevant doses of CsA and released them 
in a sustained manner for up to 5 days in vitro. The results from this study demonstrated the potential 
of the mucoadhesive NPs as a drug delivery platform to drastically improve the ocular retention time 
of the drugs on the ocular surface. 
After demonstrating the feasibility of the PBA-modified NPs as a potential eye drop delivery 
platform, we further evaluated the performance of these nanoparticles using an in vivo environment as 
a proof-of-concept demonstration. The once weekly dosing of CsA-encapsulating, PBA-modified NPs 
to rabbits showed no physical signs of irritation or discomfort, and also did not show any inflammatory 
responses in post-euthanasia histopathology analysis. The same once weekly dosing of PBA-modified 
NPs with CsA demonstrated effective treatment of dry eye in mice by eliminating ocular inflammation 
as well as restoring ocular surface goblet cells. In the same study, the commercial product of CsA, 
Restasis®, only showed elimination of ocular inflammation without showing the recovery of ocular 
surface goblet cells. These promising results led us to further investigate the pharmacokinetic properties 
of these formulations to find the optimal dosage of the NP formulation for long term treatment of dry 
eye. 
In a subsequent study, we studied the ocular surface retention of drugs following delivery through 
the PBA-modified NPs. A near-infrared fluorescent dye, indocyanine green (ICG), was used as a model 
drug to mimic the topical delivery of drugs using PBA-modified NPs. ICG delivered using the PBA-
modified NPs demonstrated ocular retention for up to 24 hours, whereas the ICG delivered without the 
NPs only remained for up to 3 hours.  
We further reduced the dosage of the Cyclosporine A in the NPs to determine their effect on the long 
term treatment of dry eye in mice. Restasis® and NPs carrying 21-fold lower dosage of CsA compared 
to that of Restasis® both showed elimination of ocular inflammation but also failed to recover ocular 
surface integrity. NPs carrying 50- to 100-fold lower dosage of CsA with respect to Restasis® showed 
both the elimination of ocular inflammation and the full recovery of ocular surface integrity, including 
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restoration of ocular surface goblet cells. All the results thus far demonstrate the feasibility of the PBA-
modified NPs to move forward into clinical trials. 
One of the key requirements to meet to go into clinical trials is to have a scalable manufacturing 
process that can meet the standards posed by the Food and Drug Administration (FDA). Since the 
procedure that we introduced in Chapter 4 is not easily scalable, we developed a new process that can 
synthesize the PBA modified PLA-Dex block copolymer in a fast, simple, and scalable manner using 
a semi-solid reaction mechanism. The amount of PBA grafted onto the dextran backbone was tuneable 
by changing the reaction temperature and the duration, as well as the ratio of ingredients in the reaction. 
Within 10 minutes of reaction, the semi-solid state process yielded PBA/dextran with a conjugation 
efficiency comparable to the method developed in Chapter 4. 
8.3 Recommendations for future work 
The following research and development tasks are recommended based on the conclusions drawn from 
this thesis to further advance this project into clinical trials and beyond: 
1. Demonstrate the manufacturing process of the NP-drug eye drop formulation with an acceptable 
shelf-life. Chapter 7 describes the process for synthesizing the block copolymers in a scalable 
manner. The next task is to develop a manufacturing process for the final NP-drug eye drop 
formulation in a scalable process with an acceptable shelf-life, depending on the drug of choice. 
2. Investigate the pharmacokinetic and ocular biodistribution of drugs delivered through 
mucoadhesive NPs. In addition to investigating the ocular surface retention of drugs delivered using 
the NP formulation, we must also investigate how the drugs are distributed on the ocular surface 
and how much of it penetrates deep into the ocular tissues and perhaps ends up in the blood stream. 
These are key questions to address in order to understand the biocompatibility of the formulation 
and to optimize the dosage of the drugs in the formulation to treat various ocular diseases. 
3. Demonstrate good manufacturing practice (GMP) process for formulating the NP eye drops as well 
as good laboratory practice (GLP) level safety and efficacy studies using the NP eye drop 
formulation. GMP level production of the formulation and GLP studies to demonstrate the 
biocompatibility and the efficacy in treatment are key factors in determining the approval of the 
formulation to advance to the clinical stage. 
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4. Optimize the drug dose and the dosing frequency of the NP formulation from the GLP studies. 
Once GLP studies have demonstrated the safety and efficacy, another key question to address is 
the optimal drug concentration and its administration frequency to treat ocular diseases.  
5. Submit an investigative new drug (IND) application to obtain approval to perform clinical trial 
phases I, II, and III. With the successful completion of all the studies described above, we can 
submit the IND application with all the necessary data for approval from the appropriate 
government agencies to proceed to the clinical trials. 
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Appendix A 
Covalent linkage between phenylboronic acid and sialic acid for 
mucoadhesive targeting 
 
Figure 35. Verification of covalent complexation between the phenylboronic acid (PBA) on the 
PLA-Dex NPs with sialic acid. The intrinsic fluorescence of PBA (excitation: 288 nm; emission 
376 nm) is quenched in the presence of sialic acid (SA) due to the covalent complexation 
between PBA and sialic acid. 
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